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ABSTRACT
Murine norovirus (MNV) is a positive-sense, plus-stranded RNA virus in the Caliciviri-
dae family. It is the most common pathogen in biomedical research colonies. MNV is
also related to the human noroviruses, which cause the majority of nonbacterial gastroen-
teritis worldwide. Like the human noroviruses, MNV is an enteric virus that replicates
in the intestine and is transmitted by the fecal-oral route. MNV replicates in murine
macrophages and dendritic cells in cells in culture and in the murine host. This virus is
often used to study mechanisms in norovirus biology, because human noroviruses are
refractory to growth in cell culture. MNV combines the availability of a cell culture and
reverse genetics system with the ability to study infection in the native host. Herein, we
describe a panel of techniques that are commonly used to study MNV biology. Curr.
Protoc. Microbiol 33:15K.2.1-15K.2.61. C© 2014 by John Wiley & Sons, Inc.
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INTRODUCTION
Murine norovirus (MNV) is a small non-enveloped virus with a plus-sense RNA genome
7.5 kb in length. MNV is a member of the calicivirus family, norovirus genus, and all
strains isolated to date are exclusively found in norovirus genogroup V (Green, 2007).
MNV is highly abundant in research mice (e.g., Hsu et al., 2005; Kitajima et al., 2009;
Mahler and Kohl, 2009). MNV-1 was originally isolated from immunocompromised mice
(Karst et al., 2003), but later shown to infect wild-type mice (Mumphrey et al., 2007;
Chachu et al., 2008). Many different strains of MNV have been isolated from wild-
type or genetically modified mice in biomedical research colonies (e.g., Thackray et al.,
2007). MNV has also been detected in wild rodents (Smith et al., 2012; Tsunesumi et al.,
2012). It is the only norovirus that efficiently grows in tissue culture (in macrophages and
dendritic cells) and in a small animal host (Karst et al., 2003; Wobus et al., 2004, 2006).
Many biological features, including fecal-oral transmission, replication in the intestine,
and fecal shedding are shared between murine and human noroviruses (Wobus et al.,
2006). Therefore, MNV is often used as a model to study norovirus biology.
The following protocols describe a variety of methods typically used to analyze different
aspects of MNV biology. The protocols begin with a description of how to generate viral
stocks and purify MNV (Basic Protocol 1 and Alternate Protocol 1). This is followed
by a method to measure anti-MNV antibodies in sera of mice to verify whether mice in
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biomedical research colonies are seronegative prior to their use in experiments (Basic
Protocol 2). Next, three different protocols to generate MNV mutants are described (Basic
Protocol 3, Alternate Protocol 2, Basic Protocol 4), followed by measuring viral titers
either by detection of infectious particles or genome (Basic Protocol 5, Alternate Protocol
3, and Alternate Protocol 4). Basic Protocol 6 describes strand-specific quantification of
MNV-1 RNA. The unit ends with protocols describing several methods to modulate a
host gene of interest in a variety of cell lines or primary cells to study its effect on MNV
infection (Basic Protocols 7 to 9 and Alternate Protocol 5).
CAUTION: MNV is a Biosafety Level 2 (BSL-2) pathogen in some countries (e.g.,
U.S.A.). Follow all appropriate guidelines and regulations for the use and handling of
pathogenic microorganisms.
NOTE: All solutions and equipment coming into contact with living cells must be sterile,
and aseptic techniques should be used accordingly.
NOTE: All culture incubations should be performed in a humidified 37°C, 5% to 10%
CO2 incubator unless otherwise specified.
BASIC
PROTOCOL 1
GENERATION OF MURINE NOROVIRUS-CONTAINING CELL LYSATE
This procedure outlines the making of a MNV-containing cell lysate (hereafter referred
to as MNV stock). We describe the generation of an MNV-1 stock by infecting RAW
264.7 cells. However, this protocol can be used with other MNV strains and other cell
lines that support viral replication and yield high viral titer, such as SRDC or BV-2 cell
lines (Blasi et al., 1990; Ruiz et al., 2005). The MNV stock is useful for a wide range of
applications, such as virus concentration and purification (see Support Protocols 1 and
2). Depending on the MNV strain, viral titers of 106 to 107 pfu/ml are routinely obtained
after 2 days of infection.
Materials
RAW 264.7 cells (ATCC no. TIB-71)
Complete DMEM-10 medium (see recipe)
MNV-1 (available via materials transfer agreement from Dr. Herbert Virgin,
virgin@wustl.edu; or other murine norovirus strains of interest)
175-cm2 tissue culture-treated flasks
Cell scraper (e.g., Sarstedt—39 cm)
Sterile, disposable plastic tubes for storing the lysate and aliquots
Additional reagents and equipment for determining viral titer by TCID50 (Basic
Protocol 5) or plaque assay (Alternate Protocol 3)
Culturing of RAW 264.7 cells for MNV-1 expansion
1. Scrape RAW 264.7 cells from a confluent 175-cm2 flask.
2. Resuspend RAW 264.7 cells in fresh complete DMEM-10 medium and make a
single-cell suspension.
3. Seed cells at a density of 4 × 107 cells per 175-cm2 flask in 30 ml of complete
DMEM-10.
This is roughly a 1:3 dilution of a confluent flask. Be sure to resuspend the RAW 264.7
cell well to obtain a single-cell suspension.
RAW 264.7 cells infection
4. Infect cells with MNV-1 at MOI = 0.05 by pipetting virus directly into the medium
using a pipettor. Carefully mix virus with medium after flask has been closed.
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MNV-1 harvest and storage
6. Check cells for the presence of cytopathic effect (CPE).
CPE can be easily observed, since the cell monolayer will be detaching from the flask. If
most cells are still attached, incubate for a few more hours.
7. Dislodge any remaining attached cells by hitting the side of the flask.
8. Pool contents from all flasks and transfer cell lysate containing virus into a sterile
container.
9. Freeze lysate at −80°C, then thaw. Repeat.
10. Aliquot lysate and store at −80°C.
Frozen lysate is stable for months to years at −80°C. However, avoid repeated freeze/thaw
of virus stocks (i.e., more than five times).
11. Determine viral titers by TCID50 (Basic Protocol 5) or plaque assay (Alternate
Protocol 3).
It is best to titer MNV-1 regular stock at least three times independently before calculating
the final virus titer of the stock.
SUPPORT
PROTOCOL 1
GENERATION OF A CONCENTRATED MURINE NOROVIRUS STOCK
This protocol describes the process of generating a concentrated MNV stock from MNV-
containing cell lysate (see Basic Protocol 1). The concentrated MNV stock is used
for techniques that require higher virus titers typically obtained by growing MNV in
RAW 264.7 cells (i.e., 106 to 107 pfu/ml). The MNV concentrated stock is particularly
important for animal challenge experiments, due to the small size of the host and the
intrinsic limitations on the volume that can be administered to mice by the different
infection routes. Typically, one can expect a 2log increase over the MNV lysate. So if the
MNV stock titer is 107 pfu/ml, one can expect an MNV concentrated stock titer around
109 pfu/ml.
Materials
MNV stock (see Basic Protocol 1)
30% (w/v) sucrose solution in tissue-culture PBS, filter sterilized with 0.22-μm
filter (e.g., Millipore Stericup Express Plus system)
Phosphate-buffered saline (PBS), pH 7.4, sterile (e.g., Life Technologies, cat.
no.10010-023)
Refrigerated tabletop tissue culture centrifuge (e.g., Sorvall Legend RT)
36 ml clear ultra-centrifuge tubes (e.g., Beckman-Coulter, cat. no. 344058)
Ultracentrifuge (e.g., Sorvall WX Ultra 80) with rotor and buckets for the
appropriate volume (e.g., Sorvall AH-629)
Additional reagents and equipment for determining viral titer by TCID50 (Basic
Protocol 5) or plaque assay (Alternate Protocol 3)
1. Thaw MNV stock and break apart cell debris by vigorously vortexing the virus-
containing lysate.
2. Pellet large cell debris by centrifugation in tabletop tissue culture centrifuge for
20 min at 2000 × g, 4°C.
3. Pool supernatants.
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5. Very carefully overlay lysate (30 ml) onto sucrose cushion.
It is imperative to add lysate very slowly onto the sucrose cushion to minimally disturb
it.
The ultracentrifuge tubes should be full in order to minimize protocol duration and
prevent cracking of the tubes (leave around 0.5 cm free to prevent spilling).
6. Balance all tubes and load into ultracentrifuge rotor.
7. Centrifuge in AH-629 rotor 3 hr at 95,000 × g, 4°C.
8. Discard supernatant.
9. Repeat steps 4 to 8 until all lysate has been pelleted.
We use the same tubes twice in order to minimize the volume and thus increase virus titer
per volume.
10. Add 200 μl of tissue-culture PBS per tube to resuspend pellet.
11. Seal tubes (e.g., Parafilm) and incubate overnight at 4°C.
The incubation period is necessary to allow pellet to loosen and to be easily resuspended.
12. Pool the contents of all tubes.
13. Rinse each of the six ultra-centrifuge tubes with 500 μl of tissue-culture PBS and
combine with the previously pooled concentrated MNV stock (from step 12).
14. Aliquot concentrated MNV stock into 2-ml screw cap tubes and store at −80°C.




PURIFICATION OF MNV BY CESIUM CHLORIDE DENSITY GRADIENT
CENTRIFUGATION
This protocol describes the purification of MNV particles from cellular debris based on
differential density of virions and cellular proteins/protein complexes. Several different
protocols have been published for cesium chloride purification of caliciviruses (e.g.,
Madore et al., 1986; Parwani et al., 1990). They mainly differ in the way the virus is
released from cells, the method for concentration of virus particles prior to purification,
and the number of density gradients performed. The protocol described below is a
very basic one that includes relatively few steps. It is designed for the purification of
approximately 180 ml of MNV stock (see Basic Protocol 1). For purification of MNV
from larger volumes, see Alternate Protocol 1. Keep virus-containing solutions cold
whenever possible.
Materials
MNV stock (see Basic Protocol 1)
30% (w/v) sucrose solution PBS, filter sterilized with 0.22-μm filter (e.g.,
Millipore Stericup Express Plus system)




Refrigerated ultracentrifuge and Beckman rotors SW32 and SW55
Ultraclear centrifuge tubes for SW32 (Beckman Coulter, cat. no. 344058) and
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Refractometer
22-G needles
10 kDa MWCO dialysis tubing
Dialysis clips
Additional reagents and equipment for dialysis (Zumstein, 1998) and SDS-PAGE
including gel staining (APPENDIX 3M)
1. Freeze/thaw flasks containing MNV-containing cell lysate.
This protocol is for 180 ml lysate from six 175-cm2 flasks, with 30 ml medium in each
flask.
2. Break apart cell debris by vortexing flasks containing cell lysate. Pool all lysates.
3. Centrifuge lysate 20 min at 2000 × g, 4°C, in a tabletop tissue-culture centrifuge to
pellet large cellular debris. Save supernatant.
4. Place 5 ml of 30% sucrose solution in bottom of a SW32 Beckman Ultraclear
centrifuge tube. Very slowly layer 30 ml supernatant on top of 30% sucrose cushion
and place in SW32 rotor.
Do not mix the solutions. The clear sucrose solution and the phenol-red containing lysate
should be clearly separated.
5. Repeat step 4 for the other five centrifuge tubes. Make sure that all tubes are balanced
before starting the ultracentrifuge; use remaining cell lysate or PBS to balance tubes.
Prepare a total of six tubes, one for each bucket of the SW32 rotor.
6. Centrifuge 3.0 hr at 130,000 × g, 4°C.
Make sure all tubes are balanced and have the same weight before starting the ultracen-
trifuge.
7. Discard the supernatant. Place tube upside down on paper towel to drain remaining
solution.
A slightly yellowish/brownish pellet should be visible at the bottom of each tube.
8. Suspend the viral pellets from three tubes in 1 ml PBS. Rinse all tubes with 0.5 ml
PBS. Pool all supernatants into a final volume of 2.5 ml.
Make sure pellets are completely resuspended. You may have to incubate the pellet with
PBS for several hours at room temperature or at 4°C overnight. If chunks remain, vortex
the pooled supernatant vigorously and pipet up and down to completely dissolve pellets.
This will increase yields. In addition, rinse tubes with PBS to prevent excess loss of virus.
9. Suspend 1.9 g CsCl in 2 ml PBS.
10. Mix dissolved pellet with CsCl solution. Check the refractive index (RFI) using
a refractometer and adjust to 1.365 to 1.367, if necessary, by adding CsCl salt to
increase the density of the solution. Add solution to SW55 centrifuge tube.
Make sure to prepare a balance tube of identical weight for the ultracentrifuge.
11. Centrifuge overnight (18 to 24 hr) at 148,000 × g, 4°C, in SW55 Ti rotor to prepare
the gradient.
12. Wipe bottom of tube with 95% ethanol, drill a hole in the bottom of the tube with a
22-G needle, and collect 0.5- to 1-ml fractions.
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14. Dialyze fractions (Zumstein, 1998) with refractive index of 1.362 to 1.373 against
two changes of 2-liters PBS, using an MWCO 10 kDa dialysis membrane overnight
at 4°C.
15. Analyze gradient fractions by running 5 μl from each fraction on an SDS-PAGE
gel and Coomassie staining (all procedures described in APPENDIX 3M) to check the
purity.
The capsid protein should be visible 58 kDa.
ALTERNATE
PROTOCOL 1
PURIFICATION OF MNV BY CESIUM CHLORIDE DENSITY GRADIENT
CENTRIFUGATION (LARGE-SCALE)
This protocol is designed for use with 1 liter of MNV stock (see Basic Protocol 1 on how
to generate the virus stock). This protocol can be adjusted to accommodate even larger
volumes of virus lysate. It also includes a solvent-extraction step to separate virus from
cellular debris. Keep virus-containing solutions cold whenever possible.
Materials
MNV stock (Basic Protocol 1)
NaCl
PEG 8000
Phosphate-buffered saline (PBS), pH 7.4, sterile (e.g., Life Technologies, cat. no.
10010-023)
Vertrel XF (non-hazardous freon substitute; DuPont)
CsCl gradient solutions with densities of 1.35 and 1.45 g/cm3
95% ethanol
Mid-speed centrifuge with SLA-3000 rotor and buckets
Stir plate in cold room with beaker and stir bar
Sonicator with sonicator tip (e.g., Fisher Scientific, Sonic Dismembrator model
550)
Beckman Coulter Ultracentrifuge with SW32 rotor and tubes
22-G needles
Refractometer
10 kDa MWCO dialysis tubing
Dialysis clips
Additional reagents and equipment for dialysis (Zumstein, 1998) and SDS-PAGE
including gel staining (APPENDIX 3M)
Virus concentration with PEG 8000
1. Thaw 1 liter of MNV stock (see Basic Protocol 1).
2. Freeze-thaw MNV stock two times.
3. Clarify supernatants by centrifuging them 30 min at 6000 × g, 4°C, in an SLA-3000
rotor. Save supernatants and discard pellets.
4. Determine the total volume of supernatant to be concentrated. Bring the NaCl
concentration to 1 M.
DMEM contains 6.8 g/liter NaCl, so add 51.6 g NaCl per liter of fluid to be concentrated.
5. Add PEG 8000 to a concentration of 8% (w/v).
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7. Centrifuge fluid 30 min at 17,000 × g, 4°C.
8. Discard supernatant.
Solvent extraction
9. Resuspend the pellet in 20 ml PBS. Split sample in half. Transfer to 50-ml conical
tube.
10. Sonicate for 30 sec (at setting 4.0 for the Sonic Dismembrator).
11. Add an equal volume of Vertrel XF solvent, a non-hazardous freon substitute.
12. Sonicate with microtip at 4.0 for about 1 min to make an emulsion.
13. Centrifuge 10 min at 2000 × g, 4°C.
You should see a top opalescent aqueous phase, an interphase (white), and a lower
organic phase.
14. Take the aqueous phase and repeat the solvent extraction one time.
15. Store on ice until gradient is ready.
CsCl gradient purification
16. Make a step gradient by placing 10 ml of 1.45 g/cm3 CsCl in bottom of centrifuge
tube, and then very gently overlaying with 10 ml of 1.35 g/cm3 CsCl.
17. Gently overlay 18 ml virus-containing solution onto the gradient.
Prepare another tube of same weight for balance.
18. Ultracentrifuge 48 hr at 100,000 × g, 4°C.
19. Wipe bottom of tube with 95% ethanol, drill a hole in the bottom of the tube with a
22-G needle, and collect 1-ml fractions.
20. Determine refractive index (RFI) of each fraction.
21. Dialyze fractions (Zumstein, 1998) with RFI 1.362 to 1.373 against two changes
of 2-liters of PBS overnight at 4°C, using an MWCO 10 kDa dialysis membrane.
22. Analyze fractions by running 5 μl from each fraction on an SDS-PAGE gel, and
Coomassie staining the gel (all procedures described in APPENDIX 3M) to check the
purity.
The capsid protein is 58kDa and should be clearly visible.
BASIC
PROTOCOL 2
MURINE NOROVIRUS ENZYME-LINKED IMMUNOSORBENT ASSAY
The purpose of an enzyme-linked immunosorbent assay (ELISA) is to detect and quantify
the presence of proteins, antibodies, and certain other substances in a sample. The
antigen is immobilized onto the surface of an ELISA well and then complexed with an
antibody. The antibody can be directly conjugated to an enzyme, or a secondary antibody
conjugated to an enzyme can be used. The enzyme typically catalyzes a reaction that
produces a product that is measurable, most commonly via a color change, to quantify
enzyme activity. The purpose of the MNV enzyme-linked immunosorbent assay (ELISA)
is to detect and quantify the presence of anti-MNV specific antibodies in a sample (e.g.,
mouse serum). Positive samples (i.e., containing MNV antibodies) will turn green during
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Materials
Concentrated virus (see Support Protocol 1)
Phosphate-buffered saline (PBS), pH 7.4, sterile (e.g., Life Technologies, cat.
no.10010-023)
ELISA wash buffer (see recipe)
ELISA blocking buffer (see recipe)
ELISA III buffer (see recipe)
Sera to be tested, plus known positive and negative control sera
Goat anti-mouse IgG, IgA, IgM (H+L), horseradish peroxidase conjugate (Life
Technologies, cat no. A10668)
ELISA substrate buffer (see recipe)
30% H2O2 (Fisher Scientific, cat. no. BP 2633-500)
Stop buffer (0.1 N phosphoric acid): 6.8 ml 85% phosphoric acid (14.7 N) per
500 ml water
Immulon II HB flat-bottomed ELISA plate (Thermo Labsystems)
Repeating and multichannel pipettors with reservoirs
Plate reader
Perform steps 1 to 10 in a biosafety hood
1. Calculate the number of wells and final volume of virus needed to coat the plate.
For each well, dilute 2 to 5 μl of concentrated virus in phosphate-buffered saline
(PBS) in a final volume of 100 μl.
The optimal concentration of virus for coating per well should be determined in a pilot
experiment. We typically coat with 2 μl of concentrated MNV/well.
2. Use repeating pipettor to distribute 100 μl of diluted virus solution/well into each
well of a 96-well ELISA plate, and then incubate overnight at 4°C covered with
aluminum foil.
3. On the next day, flick out virus solution into a biohazard bag, and then wash ELISA
plate once with ELISA wash buffer by submerging plate, tapping out any air bubbles.
4. Flick out buffer into a biohazard bag and then blot on a paper towel.
5. Use a multichannel pipettor to add 200 μl ELISA blocking buffer to each well, and
then incubate plate at 37°C for 2 hr covered with Parafilm.
6. While plate is blocking, use ELISA III buffer to make serum dilutions.
For screening of sera, use a 1:100 dilution analyzed in duplicate. Do not forget to include
a known negative and positive serum.
7. Flick out blocking buffer into a biohazard bag and then wash plates twice with
ELISA wash buffer (flicking out buffer into biohazard bag between washes).
Do not let plate dry.
8. Add 100 μl of the serum dilution to each well, and then incubate plate for 60 min at
37°C covered in Parafilm.
9. Dilute goat-anti-mouse HRP 1:2000 in ELISA III buffer.
10. Flick out serum dilutions into a biohazard bag and then wash plates four times with
ELISA wash buffer (flicking out buffer into biohazard bag between washes).
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The following steps can be carried out on the bench
11. Use a multichannel pipettor to add 100 μl of diluted secondary antibody per well,
and then incubate plate for 1 hr at 37°C covered in Parafilm.
12. At the beginning of the incubation periods, thaw one 12-ml aliquot of ELISA
substrate buffer per plate at room temperature in the dark.
13. Flick out antibody dilutions and then wash plates four times with ELISA wash
buffer.
Do not let plate dry.
14. Add 1 μl of 30% hydrogen peroxide per 1 ml of ELISA substrate buffer. Pour into
a plastic reservoir.
15. Use a multichannel pipettor to add 100 μl of ELISA substrate buffer to each well
and incubate for up to 10 min at room temperature.
16. Stop the assay when your negative control begins to turn color, or after 10 min
(whichever comes first), by adding 100 μl stop buffer to each well.
17. Measure absorption at 415 nm on ELISA reader.
You can use 405nm if 415 nm is absent. Numbers are expressed as optical density (OD).




DNA-BASED, POL II-DRIVEN GENERATION OF RECOMBINANT MURINE
NOROVIRUS
Reverse genetics is a powerful tool used to recover a genetically defined recombinant
virus from a cDNA clone, and can be utilized to examine the effect of mutations on
the virus life cycle in vitro and in vivo. Several reverse genetics systems have been
described (see also Basic Protocol 4 and Alternate Protocol 2). This protocol is based on
a publication by Ward et al. (2007). A DNA polymerase II promoter drives expression of
viral cDNA after transfection of a DNA plasmid containing the full-length MNV genome
into HEK293T cells. This usually yields about 103 pfu/ml of MNV. The recombinant
virus is subsequently amplified in RAW 264.7 cells to yield between 106 and 107 pfu/ml
of MNV in RAW 264.7 cells.
Materials
Full-length MNV-containing plasmid (pMNV; available via materials transfer
agreement from Dr. Herbert Virgin, virgin@wustl.edu)
EGFP-expressing plasmid as control for transfection efficiency
Opti-MEM I medium (Invitrogen)
Transfection reagent (Fugene HD; Promega)
293T cells (ATCC no. CRL-3216) growing in culture (low passage number works
better)
DMEM-10 medium (see recipe)
RAW 264.7 cells (ATCC no. TIB-71; if viruses are going to be passaged to RAW
cells)
QIAamp viral RNA kit (Qiagen)
Qiagen OneStep RT-PCR kit
RNasin (Promega)
10 mM dNTP mix (APPENDIX 2A)
Forward primer (GTGCGCAACACAGAGAAACG)
Reverse primer (CGGGCTGAGCTTCCTGC)
Nuclease-free H2O (APPENDIX 2A, or purchase, e.g., from Invitrogen)
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25-, 75-, and 175-cm2 culture flasks
15-ml screw-cap tubes




Additional reagents and equipment for determining viral titer by TCID50 (Basic
Protocol 5) or plaque assay (Alternate Protocol 3), agarose gel electrophoresis
(Voytas, 2000), and spectrophotometric quantitation of DNA (Gallagher, 2011)
NOTE: All steps are carried out at room temperature. Media should be warmed to 37°C
or equilibrated to room temperature. Transfect 293T cells with MNV plasmid
1. Dilute 1.5 μg MNV plasmid in 94 μl Opti-MEM I in a 1.5-ml microcentrifuge tube.
Opti-MEM I used for the transfection reaction mix should NOT have added serum or
antibiotics
Include the EGFP-expressing plasmid as a control for transfection efficiency.
2. Add 6 μl Fugene HD to the Opti-MEM-plasmid mix and briefly vortex (for about
2 sec) on high. Spin down transfection mix for 10 sec at 8000 × g.
The ratio of plasmid to Fugene HD is usually 1:4, but you can try other ratios to determine
the best combination for your plasmid. Fugene HD sticks to plastics so avoid touching the
plastic wall of the tube by pipetting directly into the solution. Take Fugene HD directly
from the refrigerator, vortex before use, and put it back after pipetting. Warming Fugene
HD is not necessary.
3. Incubate solutions for 15 min at room temperature.
Do not to exceed 25 min. If you are transfecting many plasmids, make sure you can
proceed with the first sample after a 15-min incubation.
4. In the meantime, harvest 293T cells. Aspirate the medium and add 10 ml of fresh
DMEM-10 medium. Dislodge the cells by hitting the flask. Centrifuge cells 5 min
at 200 × g, room temperature, remove the supernatant, and resuspend cells at 1 ×
107 cells/ml in DMEM-10.
Healthy 293T cells are easily dislodged from the flask. If the cells have a problem
dislodging, then you may want to use a fresh batch. The effect of trypsin on 293T is not
yet established, so you should stay away from it during this step.
5. Add 100 μl of the cell suspension (1 × 106 cells) to the centrifuge tube containing
transfection mix and incubate for 5 to 10 min.
6. Label 75-cm2 flasks and add 10 ml of DMEM-10 culture medium to each flask.
It is OK for 293T culture medium to have antibiotics at all times.
7. Transfer transfection mix with cells into 75-cm2 flask. Rinse centrifuge tube with
1 ml medium from the prepared 75-cm2 flask and add to flask. Incubate for at least
48 hr at 37°C with 5% CO2.
If incubation time will be 72 to 96 hr, replace medium on 293T cells with 10 ml culture
medium the next day.
Passage onto RAW 264.7 cells (liquid passage)
8. The day before passage, plate 4 × 107 RAW 264.7 cells per 175-cm2 flask.
9. Freeze 293T cells at −80°C and thaw the frozen cells at 37°C.
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11. Transfer lysate into 15-ml screw-cap tube.
12. Spin 5 min at 2500 × g, 4°C.
13. Infect RAW 264.7 cells in 175-cm2 flask with 5 ml of cleared 293T lysate (from
step 12) and 25 ml DMEM-10 medium.
14. Incubate for at least 48 hr at 37°C with 5% CO2 or until cytopathic effect is seen.
Harvest recombinant viruses
15. Freeze RAW 264.7 cells at −80°C and thaw the frozen cells at 37°C.
16. Repeat step 15.
17. Transfer lysate into 50-ml conical centrifuge tubes.
18. Spin 5 min at 2500 × g, 4°C.
19. Save supernatant. For short-term storage (1 to 2 days) store at 4°C. Otherwise, freeze
at −80°C.
Determine titer of recombinant virus
20. Use plaque assay (see Alternate Protocol 3) or TCID50 (see Basic Protocol 5) to
confirm the presence of viruses both in the cleared lysates from 293T and RAW
264.7 cells.
Plaque purification (optional)
21. Pick a plaque from a plate prepared in step 20 with a sterilized glass Pasteur pipet
by punching the pipet through the overlay into the plaque.
Pick up to five plaques and freeze up to four at −80°C in case you need more plaques to
sequence and get the desired virus.
22. Transfer the agar plug into 500 μl DMEM-10 medium and vortex.
23. Infect RAW 264.7 cells in a 25-cm2 flask containing 5 ml culture medium plus
200 μl of the medium containing the agar plug.
24. Repeat step 14.
25. Harvest virus as described in steps 15 to 19.
26. Extract RNA from 140 μl virus lysate using the QIAamp viral RNA kit according
to the manufacturer’s recommendations.
27. Prepare a 50-μl RT-PCR reaction with the following components in a PCR tube
for reverse transcription (RT) of viral RNA to cDNA using the Qiagen OneStep
RT-PCR kit.
10.00 ml 5× Qiagen OneStep reaction buffer
0.50 μl RNasin
2.00 μl 10 mM dNTP mix
2.00 μl 25 μM forward primer
2.00 μl 25 μM reverse primer
2.00 μl Qiagen Enzyme mix (from OneStep kit)
26.50 μl nuclease-free H2O
5.00 μl RNA template (step 26).
28. Centrifuge the PCR tube briefly (5 sec) to collect the reaction mixture at the bottom
of the tube. Animal RNA
Viruses
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29. Place the tube in a thermal cycler and perform PCR using the following parameters:
1 cycle: 30 min 50°C (reverse transcription)
1 cycle: 15 min 95°C (initial denaturation)
40 cycles: 30 sec 94°C (denaturation)
15 sec 55°C (annealing)
1 min 72°C (extension)
1 cycle: 10 min 72°C (final extension)
1 cycle: Indefinitely 4°C (hold).
30. Run 5 μl of the PCR reaction on a 1% agarose gel (Voytas, 2000) to confirm your
cDNA.
31. Remove primers from the PCR product using QIAquick PCR purification kit ac-
cording to the manufacturer’s recommendations.
32. Determine the concentration of your cDNA with a spectrophotometer.
33. Send cDNA sample with primers for sequencing according to the sequencing com-
pany’s instructions.
34. Compare your sequencing results with published MNV sequences using the basic
local alignment search tool (BLAST) on the NCBI Web site.
ALTERNATE
PROTOCOL 2
DNA-BASED, T7-DRIVEN GENERATION OF RECOMBINANT MNV
The recovery of murine norovirus (MNV) from transcripts generated from cDNA, in a
process driven by T7 polymerase, is a robust, reproducible, and rapid method that yields
high recovery titers of infectious MNV (Fig. 15K.2.1). The protocol described below
comprises seeding of transfectable cells permissive for MNV replication, infection with
recombinant fowlpox virus (FPV-T7) for the expression of T7 RNA polymerase (see
Support Protocol 3), and subsequent transfection of cDNA containing the MNV genome
under the control of a T7 RNA polymerase promoter (Fig. 15K.2.2). After an appropriate
incubation period, the infectious MNV particles can be titrated in suitably susceptible
cells. A video is available at http://www.jove.com/video/4145/reverse-genetics-mediated-
recovery-of-infectious-murine-norovirus.
Materials
Cultures of transfectable cells permissive for MNV replication, i.e., baby hamster
kidney cells (BHK), BSR-T7 (BHK-21-derived cells expressing recombinant
T7-polymerase), human embryonic kidney cells (HEK-293T), human
hepatocellular carcinoma cells (Huh7), or African green monkey cells (COS-7)
Titered stock of FPV-T7 (Support Protocol 3)
Dulbecco’s modified Eagle’s medium (DMEM; Life Technologies) with 10% fetal
bovine serum (FBS) and no antibiotics
Opti-MEM I medium (Invitrogen)
cDNA clone of MNV under the control of a T7 RNA polymerase promoter (i.e.,
pT7:MNV-1 3′Rz; full-length MNV–containing plasmid has been produced in
Ian Goodfellow’s laboratory and its generation has been described in Chaudhry
et al., 2007, and Yunus et al., 2010)
Lipofectamine 2000 (Invitrogen)
35-mm dish
Additional reagents and equipment for basic cell culture techniques including
trypsinization and cell counting (Phelan, 2006)
1. Trypsinize (Phelan, 2006) a confluent flask of BHK or BSR-T7 cells. For transfec-






















Figure 15K.2.1 Genome organization of MNV. (A) MNV encodes four open reading frames (ORFs). ORF1 is
translated into a precursor polyprotein that is autocatalytically cleaved to release at least six nonstructural proteins,
NS1-7. ORF2 encodes the major capsid protein VP1, while ORF3 encodes the minor capsid protein VP2. ORF4
overlaps with ORF2 at a +1 frame and encodes VF1. During replication, MNV translates from a genomic and
subgenomic RNA, both of which include VPg at the 5′ end and a poly(A) tail at the 3′ end of varying lengths.
(B) Schematic of the recovery of infectious MNV from cDNA plasmid (representative example, pT7:MNV-1 3′Rz).
The MNV cDNA sequence is downstream of the T7 promoter sequence, which allows for the T7-driven transcription
of MNV. At the 3′ extremity, MNV cDNA is fused to a 26-nucleotide long poly(A) tail. Downstream of MNV cDNA, the
sequence for a self-cleaving ribozyme is fused to generate an authentic 3′ end.
antibiotic-free DMEM supplemented with 10% FBS. Gently rock the dish to ensure
even distribution of cells and incubate the plates at 37°C (with 5% to 10% CO2) to
settle overnight. If you wish to perform the transfection on the same day, seed 1.5 ×
106 cells and leave cells to adhere for a 2- to 3-hr period at 37°C (5% to 10% CO2)
prior to proceeding to the next step.
This protocol is optimized for the use of BHK or BHK-derived BSR-T7 cells. Further
optimization is necessary if other transfectable cell lines are to be used. Parameters to
consider include cell seeding density, multiplicity of infection of FPV to be used, amount
of plasmid to be transfected, and incubation period following transfection.
2. Remove the growth medium from the cells and add 700 μl of FPV-T7 at a multiplicity
of infection of 0.5 pfu/cell. For optimal recoveries in BHK and BSR-T7 cells, ensure
that FPV is diluted to infect at a multiplicity of infection of 0.5 pfu/cell.
FPV-T7 should be prepared and titrated in primary chicken embryo fibroblast (CEF) cells,
as detailed in Support Protocol 3. The optimal amount of FPV-T7 must be determined for
each cell line, as the rate of infection differs.
The left-over FPV-T7 aliquot that has been used for recoveries should be marked before
freezing again, as the titer of the aliquot might have dropped. We suggest combining
several aliquots that have been thawed once and aliquotting them into new aliquots. The
virus titer for this stock of recycled FPV-T7 should be determined before use.
3. Leave cells for 1 hr at 37°C (with 5% to 10% CO2) to allow infection with FPV-T7.
Add 2 ml of antibiotic- free DMEM supplemented with 10% FBS, and leave cells



































Figure 15K.2.2 Schematic of recovery procedure. (1) Transfectable cells (i.e BSR-T7 or BHK)
are infected with FPV-T7. (2) Following cell entry, FPV-T7 transcription and translation results
in the production of T7 RNA polymerase. (3) After cells are left to incubate for 2 hr to allow for
the production of T7 RNA polymerase, pT7:MNV-1 3′Rz is transfected using Lipofectamine 2000.
(4) pT7:MNV-1 3′Rz is transcribed in the cytoplasm, driven by the FPV-T7 encoded T7- RNA
polymerase, to produce MNV RNA transcripts. (5) The self-cleaving δ-ribozyme that is encoded
by pT7:MNV-1 3′Rz generates an authentic 3′ end. It is possible that capping enzymes produced
by FPV-T7 are able to cap MNV RNA transcripts. (6) Capped MNV RNA transcripts are trans-
lated for the production of MNV proteins. VPg linked MNV RNA transcripts undergo replication.
(7) Nascent MNV RNA produced can be encapsidated to produce full infectious virus. Cells sub-
jected to freeze-thaw cycles can facilitate virus release. Virus yields can be subsequently titered
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Table 15K.2.1 MNV Recovery Titers from Different Transfectable Cell Lines
Cell typea Titersb with pT7:MNV-1 3′Rz
BHK 3.4 × 104 TCID50/mlc
BSR-T7 3.4 × 104 TCID50/ml
HEK 293T 6.0 × 104 TCID50/ml
Huh 7.5 2.4 × 104 TCID50/ml
aCells transfected with pT7:MNV-1 3′Rz.
bVirus yield determined 24 hr post transfection.
cTiters performed in triplicate and expressed as TCID50/ml.
It is important that no antibiotics be present in the growth medium, as this may interfere
with the lipofection process.
4. To prepare the transfection mixture, combine 100 μl of Opti-MEM I containing 1 μg
of MNV cDNA clone that is under the control of a T7 RNA polymerase promoter,
with 100 μl Opti-MEM I containing 4 μl of Lipofectamine 2000. Mix the resultant
mixture thoroughly by gently pipetting up and down around 15 times. Allow 20 min
at room temperature for Lipofectamine 2000 to form a complex with the cDNA.
5. Aspirate the growth medium containing unattached virus off the cells (see step 3) and
gently wash once with 2 ml of antibiotic-free DMEM supplemented with 10% FBS.
Then add 3 ml of antibiotic-free DMEM supplemented with 10% FBS to cover the
cells.
6. Add the transfection mix (from step 4) in a dropwise manner to the cell monolayer
(from step 5). To ensure even distribution of the cDNA, gently rock the plates before
placing them at 37°C (with 5% to 10% CO2).
Plasmid pT7:MNV-1 3′Rz, containing the full MNV-1 cDNA genome sequence, produces
optimal titers after 24 hr incubation, though other strains may require a longer incubation
period.
As a reference, MNV-1 cDNA clone pT7:MNV-1 3′Rz requires only 24 hr to produce virus
titers above 104 TCID50/ml (Table 15K.2.1). For other strains (i.e., MNV-3), or viruses
containing deleterious mutations affecting replication, longer incubation periods may be
required for optimal yields (Arias et al., 2012).
7. Freeze cells at −80°C. Once thawed, centrifuge cells 5 min at 1000 × g, room
temperature, to pellet the cellular debris.
The virus-containing supernatant can be aliquotted and stored indefinitely at −80°C. A
frozen aliquot should be thawed and used to titrate the recoveries.
SUPPORT
PROTOCOL 3
PREPARATION OF A FPV-T7 STOCK REQUIRED FOR REVERSE
GENETICS
Preceding the recovery of MNV from genomic cDNA is the generation of a well-
characterized FPV-T7 virus stock. Expression of recombinant T7 RNA polymerase in
cells infected with FPV-T7 will drive the synthesis of replication-competent capped
viral transcripts from cDNA. The FPV-T7 strain used was initially generated by Dr Mike
Skinner, Imperial College London, and is readily available via MTA (Britton et al., 1996).
This approach will typically produce MNV-1 at a titer of >104 TCID50/ml after 24 hr.
Recovery titers from other commonly used transfectable cell lines are highlighted in
Table 15K.2.1. High-titer MNV stocks can then be produced by infecting a susceptible
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Materials
Primary chicken embryonic fibroblast cells (CEFs)
Dulbecco’s modified Eagle’s medium (DMEM; Life Technologies), supplemented
with 10% fetal bovine serum (FBS) and 1× penicillin/streptomycin
FPV-T7 inoculating stock (obtained via MTA from Dr. Mike Skinner, Imperial
College London; m.skinner@imperial.ac.uk)
Large volume flasks (175- or 225-cm2)
Additional reagents and equipment for basic cell culture techniques including
trypsinization and cell counting (Phelan, 2006)
1. Trypsinize a flask of chicken embryo fibroblasts (CEFs) primary cells and seed them
at 1 × 105 cells/ml (Phelan, 2006).
Typically, large-volume flasks (175- or 225-cm2) are seeded with CEFs to facilitate the
recovery of high volumes of FPV-T7. This seeding density equates to 5 × 106 cells in a
175-cm2 flask.
2. When cells reach 100% confluence, infect them with FPV-T7 at a multiplicity of
infection of 1 pfu/cell and incubate for 1 hr at 37°C in the presence of 5% to 10%
CO2.
3. Remove the inoculum and add DMEM supplemented with 10% FBS and 1× peni-
cillin/streptomycin to overlay the cells. Incubate the infected cell cultures at 37°C in
the presence of 5% to 10% CO2 until complete cytopathic effect is observed.
A small mock-infected cell culture should be carried out in parallel to identify cytopathic
effect in infected cultures.
For a 175-cm2 flask, a volume of 20 ml is recommended to cover the cells to enable
the recovery of higher virus titers. Complete cytopathic effect is observed within 48 and
72 hr post-infection. Typically, cytopathic effect results in the development of granular
cell morphology (Somogyi et al., 1993). A small mock-infected culture might be useful to
distinguish cytopathic effect in the infected cultures.
4. Freeze-thaw the cell cultures twice to facilitate the release of virus particles to the
supernatant.
5. Remove the cell debris from the lysates by centrifugation for 5 min at 600 × g, 4°C.
Virus preparations should not be filtered to clarify them, as FPV diameter is around 260
to 280 nm (larger than pore-diameter size in 0.2-μm filters).




RNA-BASED GENERATION OF RECOMBINANT MURINE NOROVIRUS
Infectious MNV from cDNA is efficiently recovered via in vitro transcription and sub-
sequent in vitro capping. The resulting capped RNA transcripts are then transfected into
cells to recover infectious MNV. Transcripts are transfected into either BV-2 or BSRT7
cells. BSRT7 or parental BHK cells are used to test the specific infectivity of the RNA, as
the cells are not permissive to re-infection, and virus yields represent those from a single
growth cycle. BV-2 cells are used when minimal passage in cell culture is required for a
cDNA clone that is known to be infectious.
Typically, Neon (Life Technologies)–mediated transfection of BV-2 cells can yield
around 1 × 106 TCID50/ml MNV at 24 hr post-transfection and up to 1 × 109 TCID50/ml
at 72 hr post-transfection, although this effectively constitutes the first passage of the
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A video for the generation of recombinant MNV can be found at http://www.jove
.com/video/4145/reverse-genetics-mediated-recovery-of-infectious-murine-norovirus
Materials
MNV cDNA (pT7:MNV 3′Rz) or plasmid containing recombinant MNV cDNA
NheI restriction enzyme (NEB, cat. no. R0131S)
GFX PCR DNA Gel Band Purification Kit (GE Healthcare, cat. no. 28-9034-70)
MEGAscript T7 Kit (Life Technologies, cat. no. AM1334) including reagents
tabulated in Table 15K.2.3
2 U/μl DNase I, RNase-free (NEB, cat. no. M0303S) and DNase I buffer
Lithium chloride (LiCl) precipitation solution (Life Technologies, cat. no.
AM9480)
70% ethanol
RNA storage solution (Life Technologies, cat. no. AM7000)
ScriptCap m7G Capping System (Epicentre Biotechnologies, cat. no. SCCE0610)
Neon transfection system (Life Technologies, cat. no. MPK5000)
Neon transfection system kit (Life Technologies, cat. no. MPK1025)
Opti-MEM I (Life Technologies, cat. no. 31985070)
Lipofectamine 2000 Transfection Reagent (Life Technologies, cat. no. 11668-027)
BV-2 cells (Blasi et al., 1990)
BV-2 medium: Dulbecco’s Modified Eagle Medium (DMEM) supplemented with
10% fetal bovine serum (FBS), 2 mM L-glutamine, and 1×
penicillin/streptomycin (omit antibiotics where instructed)
Phosphate-buffered saline (PBS), pH 7.4, sterile (e.g., Life Technologies, cat.
no.10010-023)
Neon transfection system (Life Technologies, cat. no. MPK5000)
Neon transfection system 10-μl kit (Life Technologies, cat. no. MPK1025)





15-ml conical tubes (e.g., BD Falcon)
35-mm culture dish
Additional reagents and equipment for quantification of nucleic acids (Gallagher,
2011), agarose gel electrophoresis of RNA (Voytas, 2000; performed in the same
way as for DNA but using RNase-free reagents), and basic cell culture
techniques including trypsinization and cell counting (Phelan, 2006), and plaque
assay (Alternate Protocol 3) or TCID50 assay (Basic Protocol 5)
NOTE: All protocol steps must be performed using RNase-free water.
Synthesis of infectious capped MNV transcripts
1. Digest 5 to 10 μg of the plasmid containing the wild-type MNV cDNA (pT7:MNV
3’Rz) or recombinant MNV cDNA with NheI to obtain linear DNA. Table 15K.2.2
shows a typical reaction setup for NheI digestion.
Table 15K.2.2 Reaction Setup for NheI Linearization of MNV cDNA
Components Final concentration Per reaction (μl)
MNV cDNA (pT7:MNV 3′Rz) 100 ng/μl Varies
10× NEBuffer 2.1 1× 10
NheI (10 U/μl) 0.2 U/μl 2

























10. Viral protein and RNA synthesis
11. Viral protein and RNA synthesis
12. Virion release by freeze-thawing
and titer determination
9. Neon transfection (BV-2)
or BSR-T7 transfection
8. RNA purification by LiCI
7. In vitro capping
6. RNA purification by LiCI
5. DNA I digestion
4. Electrophoresis analysis
3. In vitro RNA transcription
2. DNA purification by silica columns
1. Linearization of plasmid DNA
MNV cDNA (pT7:MNV 3Rz)
Figure 15K.2.3 (legend appears on next page)
NheI recognizes a unique restriction site after the 3′-end poly(A) tail of the MNV
genome; thus, it defines the 3′ end of transcription with minimal addition of nucleotides
to the 3′ end of genome (Fig. 15K.2.3).
2. Incubate the reaction mixture at 37°C for 3 hr. Purify the linearized plasmid
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Table 15K.2.3 Reaction Setup for In Vitro Transcription of Linearized MNV cDNA
Components Final concentration Per reaction (μl)
1 M HEPES, pH 7.5 100 mM 5
320 mM magnesium acetate 32 mM 5
400 mM DTT 40 mM 5
20 mM spermidine 2 mM 5
100 mM ATP 7.5 mM 3.75
100 mM CTP 7.5 mM 3.75
100 mM GTP 7.5 mM 3.75
100 mM UTP 7.5 mM 3.75
Pyrophosphatase (0.1 U/μl) 0.002 U/μl 1
RNaseOUT RNase inhibitor (40 U/μl) 1.6 U/μl 2
Water 2 (to 50 μl)
Linearized DNA 20 ng/μl 5
Recombinant T7 RNA polymerase (0.5 mg/ml) 50 ng/μl 5
Healthcare, used according to the manufacturer’s instructions) and elute in 50 μl
water.
The quality of linearized DNA is important for subsequent in vitro RNA synthesis.
Incomplete linearization or RNase contamination in the eluate will compromise the
final RNA yield and integrity, and, as such, lead to failure to generate infectious virions.
We recommend comparing 100 ng of digested and undigested DNA on an agarose gel
(Voytas, 2000) to ensure complete digestion prior to purification.
3. In vitro transcribe the linearized MNV cDNA using T7 RNA polymerase as de-
scribed below (Yunus et al., 2010).
Many commercial kits are available for this purpose and provide a reproducible method
for synthesis of large amounts of RNA, such as MEGAScript (Life Technologies) and
RiboMAX (Promega). Ensure that all equipment used, such as microcentrifuge tubes,
are certified RNase free, and use filter tips throughout this protocol. Table 15K.2.3
shows a typical reaction setup (50 μl in total; add the reagents in the order indicated).
Addition of pyrophosphatase (see Table 15K.2.3) is optional, but without pyrophos-
phatase the reaction mixture will become cloudy due to the formation of free pyrophos-
phate. This can be removed prior to precipitation by centrifugation 1 min at 12,000 ×
g and collecting the supernatant.
4. Incubate the reaction mixture at 37°C for 2 to 5 hr. Load 0.5 μl or less of the
RNA transcription reaction on an agarose gel and electrophorese (Voytas, 2000;
Figure 15K.2.3 (image appears on previous page) Overview of the protocol for the recovery of
infectious MNV from RNA transcribed and capped in vitro. The plasmid pT7:MNV 3′Rz is linearized
immediately downstream of the MNV genomic sequence using NheI restriction enzyme (step 1).
After DNA purification (step 2), MNV RNA transcripts are generated in vitro using a recombinant
T7 RNA polymerase (step 3). The RNA synthesis is confirmed by electrophoresis (step 4) and the
template DNA is eliminated using a commercial RNase-free DNase I (step 5). RNA is then purified
by an LiCl precipitation (step 6). The purified RNA product is then capped in vitro (steps 7). After
purification by LiCl precipitation (step 8), the capped RNA is transfected into either BV-2 cells using
Neon transfection system or BSR-T7 cells by lipofection (steps 9). Once inside the cell, capped
RNA transcripts will be translated into viral proteins, which should then mediate subsequent rounds
of RNA replication to generate VPg-linked RNA that can be packaged to generate infectious virions
(steps 10 to 11). To facilitate virus release from cells, one or several cycles of freeze and thaw are





















































Figure 15K.2.4 Analysis of MNV RNA transcript integrity by nondenaturing gel electrophoresis.
(A) Transcription products are run on a nondenaturing 1% agarose gel in parallel to 1-kb DNA
ladder (M, lane 1). The relative mobility of viral transcripts under nondenaturing conditions is
similar to a dsDNA product of 2.5 to 3 kb. (B) Analysis of RNA transcript after LiCl purification. (C)
Analysis of RNA integrity after capping reaction. (D) Analysis of capped-RNA integrity after LiCl
precipitation.
performed in the same way as for DNA but using RNase-free reagents) to ensure
that the reaction has worked efficiently and RNA is full-length.
Denaturing gels provide valuable indications on the size of RNA; however; nondenatur-
ing agarose gel electrophoresis provides a rapid method to analyze RNA integrity. The
MNV genome as produced from the infectious cDNA clone pT7:MNV 3′Rz will appear
as an approximately 3-kbp band relative to a dsDNA ladder on a nondenaturing TBE
agarose gel (Fig. 15K.2.4). Alternative methods for the rapid analysis of RNA integrity
include the Agilent Bioanalyzer.
The amount of RNA loaded for agarose gel electrophoresis is important for gel resolu-
tion; overloading can result in poor resolution. Also, it is essential to ensure that the
agarose gel is prepared using RNase-free reagents to avoid RNA degradation during
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5. Centrifuge the reaction mixture 1 min at 12,000 × g, 4°C, then transfer the su-
pernatant to a new RNase-free microcentrifuge tube. Next, add 2 μl DNase I
(RNase-free, 2 U/μl,), 6 μl DNase I buffer, and 2 μl water. Incubate at 37°C for
30 min before further analysis.
6. Purify the RNA sample to remove the unincorporated nucleotides. For precipitation
using LiCl, bring the final volume to 100 μl with water and then add 40 μl of LiCl
precipitation solution and store the sample at −20°C for 30 min to overnight.
The sample can be stored overnight at this point at −20°C, and the purification and in
vitro capping continued the following day.
Many other methods are available for removing unincorporated nucleotides, including
silica column–based approaches.
7. Pellet the RNA by centrifugation 15 to 30 min at 12,000 × g, 4°C.
8. Remove the supernatant and wash it in 150 μl of 70% ethanol. Centrifuge 15 min
at 12,000 × g, 4°C.
Be careful not to disturb the translucent RNA pellet when removing the supernatant.
9. Remove the ethanol and air-dry the RNA.
Avoid drying the pellet for more than 1 min, as a completely dried pellet is difficult to
resuspend.
10. Add 50 to 100 μl of RNA storage solution to resuspend the MNV transcripts.
Remove any insoluble material centrifugation for 5 min at 12,000 × g, 4°C, prior
to RNA quantification.
Care should be taken to ensure that all the RNA has dissolved properly. Heating the
sample to 60°C may help to resuspend it. The purified transcripts are uncapped and
require a subsequent in vitro capping step to be infectious (ScriptCap m7G Capping
System, Epicentre Biotechnologies; see step 13).
11. Quantify the RNA by spectrophotometry (Gallagher, 2011). Run 100 to 300 ng of
sample on a 1% RNase-free agarose gel (Fig. 15K.2.4D) to check the integrity of
RNA before performing the capping reaction.
Depending on the nature and scale of the transcription reaction, typical yields range
from 50 to 150 μg of RNA per 100 μl transcription reaction.
12. To improve the efficiency of RNA capping, heat 60 to 70 μg of MNV RNA
transcript at 65°C for 10 min, and then place the tube immediately on ice. Pulse-
spin the RNA in a chilled microcentrifuge to collect droplets formed during the
heating step at the bottom of the tube.
This step may reduce any inhibitory effect of RNA structure on the capping reaction.
13. Prepare a capping reaction mixture using the ScriptCap m7G Capping System
according to the manufacturer’s instructions.
Table 15K.2.4 is a typical reaction setup for in vitro capping reaction with a final
reaction volume of 100 μl. However, the reaction volume can be scaled down according
to the input amount of RNA and the amount of capped RNA required.
Keep RNA transcripts on ice to avoid degradation. Mix the reaction mixture thoroughly
and then incubate at 37°C for 1 hr. Purify the RNA by LiCl precipitation as described
above (see steps 6 to 10). Dissolve the pellet in 50 to 100 μl of RNA storage solution and
quantify the amount of RNA. It is convenient to adjust the RNA sample concentration
to 1 μg/μl. Again, ensure that all the RNA has dissolved properly and remove any
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Table 15K.2.4 In Vitro Enzymatic Capping Reaction
Components Final concentration Per reaction (μl)
In vitro transcribed uncapped RNA 0.6-0.7 μg/ μl Varies (total volume less than 73 μl)
10× capping buffer 1× 10
10 mM GTP 1 mM 10
20 mM S-adenosyl methionine 0.1 mM 0.5
Scriptguard (40 U/μl) 1 U/μl 2.5
Scriptcap enzyme (10 U/μl) 0.4 U/μl 4
Water Varies (to 100 μl)
14. Check the integrity of the capped RNA again before proceeding with the trans-
fection step. To do so, run 100 to 300 ng of sample on a 1% agarose gel
(Fig. 15K.2.4).
The RNA should appear as a single clean band at the correct size without evidence of
degradation or smearing and laddering of the RNA (Fig. 15K.2.4D).
For recovery by Neon-mediated transfection of capped RNA into BV-2 cells
For the recovery of MNV infectious virus in a permissive cell line it is possible to electro-
porate the capped MNV transcripts directly into BV-2 cells using the Neon transfection
system (Life Technologies). BV-2 is an immortalized murine microglial cell line that is
susceptible to MNV infection, supporting multiple rounds of virus replication and sub-
sequent re-infection (Bocchini et al., 1992; Cox et al., 2009). Yields typically approach
105 infectious units per ml or more at 24 hr post transfection and peak at >107 infectious
units per ml after 48 hr, as determined by TCID50.
15a. One day before transfection, seed BV-2 cells at an estimated 50% confluency in
BV-2 medium.
Typically a confluent 75-cm2 flask (around 8.4 × 106 cells) is sufficient for 1 transfection
reaction.
16a. On the day of transfection, aspirate the medium from the cells and detach cells using
commercial trypsin (Phelan, 2006).
17a. Neutralize trypsin using BV-2 medium (APPENDIX 4A).
18a. Pellet the cells 5 min at 1200 × g, room temperature, and resuspend in 10 ml BV-2
medium without antibiotics. Generate a single-cell suspension by repeated pipetting.
19a. Determine the density of live cells using a hemacytometer with trypan blue exclusion
(Phelan, 2006).
Each transfection requires 7.2 × 106 cells.
20a. Transfer 7.2 × 106 cells to a sterile 1.5-ml microcentrifuge tube per transfection.
Wash the cells with sterile PBS immediately prior to transfection only and pellet
2 min at 1200 × g, room temperature, in a tabletop centrifuge.
21a. Carefully remove all PBS and resuspend cells in 120 μl Buffer R (from Neon
transfection system) to achieve the desired cell density (6.0 × 106 cells/100 μl).
Here, prepare 20% extra cells and 20% extra Buffer R to prevent bubble formation
while taking cells using the Neon tip. The amount of capped RNA should be scaled
accordingly. Cells should not remain in Buffer R for prolonged periods of time due to
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22a. Add 1.2 μg of capped RNA and mix thoroughly.
23a. Place the electrode of the Neon system inside the hood and place a Neon tube (tip
holder) into the electrode. Add 3 ml Solution E from the kit to the tube.
24a. Label 6-well plates (three wells per sample) and 15-ml conical tubes. Add 9 ml
BV-2 medium (without antibiotics) to each conical tube.
Steps23a and 24a can be done during the centrifugation in step 20a. Each tip holder with
Solution E can be used for up to 10 transfections without contamination. However, when
trying to recover genetically pure viruses for further studies, it is advisable to replace
the tip holder after each transfection.
25a. Mix the cells slowly and take 100 μl BV-2 cells and RNA mixture with the Neon
tip using the Neon pipet and insert into the pipet station.
Be careful not to include any bubbles in the cell suspension. The inclusion of bubbles will
lead to sparks during the electroporation and cause cell death, which will compromise
the transfection rate.
26a. Load the following parameters for optimized BV-2 electroporation (voltage = 1700
V, width = 10 msec, and pulse = 3) and electroporate.
27a. Remove the Neon pipet from the pipet station and transfer the electroporated cells
to the 9 ml BV-2 medium in the conical tubes.
28a. Repeat steps 25a to 27a for the remaining samples.
29a. Slowly mix transfected BV-2 cells with medium and add 3 ml to each well of labeled
6-well plates.
30a. Incubate the BV-2 cells in a 37°C incubator with 5% to 10% CO2 until cells adhere
(4 to 5 hr), and then replace with medium containing antibiotics.
31a. Incubate the cells in the 37°C, 5% to 10% CO2 incubator for 24 to 72 hr. Then,
release infectious virions from cells by one (or more) freeze and thaw cycles and
determine virus titer in the sample using either plaque assay (Alternate Protocol 3)
or by TCID50 (Basic Protocol 5).
Prior to titration lysates should be clarified by centrifugation for 1 to 2 min at maximum
speed. Also, it is optional to pass the lysate through a 0.22-μm filter to exclude any cell
debris.
For recovery by transfection into BSR-T7 cells
15b. One day before transfection, trypsinize a monolayer of BSR-T7 cells (Phelan, 2006)
and seed 7.5 × 105 cells into a 35-mm diameter dish (or well of a 6-well plate) in
antibiotic-free growth medium and incubate the cells at 37°C with 5% to 10% CO2
overnight. Double the amount of cells if the transfections are planned for the same
day, and allow cells to adhere to the plate for 2 to 3 hr at 37°C with 5% to 10%
CO2.
16b. Remove the medium from the cells and replace with 3 ml of fresh medium without
antibiotics to ensure the maximum efficiency of transfection.
17b. Prepare a mixture of 1 μg of capped MNV transcript and 100 μl of Opti-MEM I and
mix it with 4 μl of Lipofectamine 2000 pre-mixed in 100 μl of Opti-MEM I. Mix
the sample thoroughly by pipetting it up and down 15 times. Incubate the mixture
at room temperature for 10-15 min.
18b. Re-mix the transfection mixture, and add to the cell monolayer in a dropwise fashion.
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19b. Incubate the cells at 37°C with 5% to 10% CO2 for 24 to 72 hr. Afterwards, release
infectious virions from cells by freezing and thawing, and determine virus titer by
plaque assay (see Alternate Protocol 3) or TCID50 (see Basic Protocol 5).
BASIC
PROTOCOL 5
MEASURING MNV TITERS BY TCID50
The tissue culture infectious dose50 (TCID50) assay is frequently used in virology to
determine virus titers. Following serial dilutions, the titer of the virus is calculated based
on forming cytopathic effect (CPE) in 50% of the infected cells after 3 to 5 days of
incubation. The procedure involves 10-fold serial dilutions of each virus sample in a
dilution plate, followed by transfer of aliquots of each sample to the test plate containing
cells, in quadruplicate. Typically, each sample is assayed as three replicates to ensure
reproducibility.
In BV-2 or RAW 264.7 cells, MNV1 is able to achieve high titers of 107 or 108 following
low-MOI (0.01 TCID50 units/cell) infection and incubation for 24 to 48 hr. At that time,
cytopathic effect is clear in both cells, with the cells lifting of the bottom of the dish,
shrinking in size and becoming apoptotic.
Materials
Frozen virus supernatant samples for titration (see protocols above)
BV-2 mouse microglial cells (or RAW 264.7 mouse macrophage cells) growing in
culture
DMEM-10 medium (see recipe)
96-well tissue culture plates
30- to 300-μl Eppendorf Research Plus multichannel pipettor
10 to 100 μl Eppendorf Research Plus multichannel pipettor
300-μl sterile filter pipet tips
1. Take out frozen samples for analysis and thaw them at 37°C or room temperature.
For an accurate titer, samples should be prepared in triplicate.
2. Transfer 100 μl to 1 ml of each sample into a sterile microcentrifuge tube.
3. Centrifuge 3 min at 13,000 × g, room temperature, in a benchtop microcentrifuge
to pellet cellular debris, and transfer the supernatant to a fresh tube.
4. Add 25 μl of each virus supernatant to the first well (row H) of the 96-well plate, as
shown in Figure 15K.2.5A.
5. Using a 30 to 300 μl Eppendorf Research plus manual pipettor, transfer 225 μl of
medium to all wells in the dilution plate, adding to the wells containing undiluted
virus (row H, Fig. 15K.2.5A) last. Pipet samples up and down three times to mix.
6. Eject tips, transfer 25 μl from the diluted virus sample to the next row (row G),
and mix thoroughly. Repeat this for each subsequent row until the dilution series is
complete, ensuring that the tips are changed after each dilution (Fig. 15K.2.5A).
7. Take a 75-cm2 flask of BV-2 cells that have reached 75% to 100% confluence.
Change the medium by adding 10 ml of DMEM-10 medium. Then, scrape the
cells and add 9 ml of medium for each ml of cell suspension—e.g., for 10 ml cell
suspension add 90 ml of medium.
RAW 264.7 cells may be substituted for BV-2 cells.
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Figure 15K.2.5 Preparation of serial dilutions, and aliquotting of diluted samples. (A) Serial
dilutions of the virus are prepared in triplicate from row H to row A in the dilution plate. (B) 50 μl
of each dilution is transferred from the dilution plate to four columns of the test plate.
9. Dispense 100 μl of cells into each well of a new, labeled test 96-well plate (test
plate) using a multichannel pipettor.
10. Using a multichannel pipettor, transfer 50 μl of each dilution from the dilution plate
into four columns of the test plate as shown in Figure 15K.2.5B.
11. Incubate at 37°C for 3 to 5 days. Check cytopathic effects (CPE) in each well. Score
each well in a dish as either infected or uninfected.
In BV-2 cells, CPE is apparent as cells dying and floating off the base of the dish,
compared to a confluent monolayer in uninfected cells.
12. Calculate TCID50 values by the Reed & Muench method (Reed and Muench, 1938;
Lindenbach, 2009).


















% ve wells 100 75 25 0
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PD  (75%–50%)/(75%–25%) 0.5
D Calculating logTCID50:
Log TCID50  (log dilution at or above 50% positive)  (PD)
From this example:
Log TCID50  (6)  0.5  6.5
E Calculating TCID50/ml
TCID50/ml  (1/10
logTCID50) / dilution factor
From this example:
TCID50/ml  (1/10
6.5) / 0.5  6.32  107 TCID50/ml
(% positive at or above 50%–50%)




Dilution 105 106 107 108
1 1 1
Figure 15K.2.6 Manual calculation of TCID50/ml values. (A) An example TCID50 result, also
given in table format in (B). (C) Calculation of the proportionate distance (–PD). (D) Using –PD to
calculate logTCID50. Calculation of TCID50/ml from the logTCID50 and dilution factor.
The dilution at which 50% of the wells are infected is calculated using the following
equation:
(% positive at or above 50%) − 50%
(% positive at or above 50%) − (% positive below 50% ) = proportionate distance(−PD)
Equation 15K.2.1
The proportionate distance (PD) is the result of the distance between the two dilutions that
gave a percentage if infection is either side of 50%. Note that the PD has a minus sign in front.
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(log dilution at or above 50%) + (–PD) = log TCID50
This log TCID50 value is then used to express the virus titer as TCID50/unit volume, e.g.,
TCID50/ml.
TCID50/ml = (1/10logTCID50)/dilution factor
In this method, 50 μl of virus is added to each well, so the dilution factor is 0.05.
For simplicity, an Excel spreadsheet created by Dr. Brett D. Lindenbach may be used for the




MEASURING MNV TITERS BY PLAQUE ASSAY
The plaque assay is used to measure infectious virions in a given sample. It is based on
the published protocol by Gonzalez-Hernandez et al. (2012), and is an alternative method
to the TCID50 assay. Compared to TCID50, the plaque assay is shorter by 1 to 3 days.
In the procedure, dilutions of a virus stock are incubated with cell monolayers, overlaid
with agarose, and stained with neutral red to visualize plaques after 2 days. A video of the
plaque assay can be found at http://www.jove.com/video/4297/plaque-assay-for-murine-
norovirus.
Materials
RAW 264.7 cells (ATCC no. TIB-71)
DMEM-10 (see recipe)
3% (w/v) SeaPlaque agarose (see recipe), prewarmed
Complete 2× MEM medium (see recipe)
Virus supernatant samples for titration (see protocols above)
0.33% Neutral Red solution (Sigma, cat no. N2889)
Phosphate-buffered saline (PBS), pH 7.4, sterile (e.g., Life Technologies, cat.
no.10010-023)






1. Plate cells at 2 × 106 cells per well of a 6-well plate in 2 ml DMEM-10 (i.e., 1 ×
106 cells/ml). Incubate cells overnight at 37°C in 5% CO2.
2. Label plates and organize them based on the samples you will be testing.
A suggestion for an efficient biosafety hood setup is shown in Figure 15K.2.7.
3. Add medium to 24- or 48-well plate for the number of dilutions that you are using
and label them (for −1 dilutions in duplicate add 1.35 ml of medium to each well,
and for −2 dilution add 1.5 ml of medium per well).
Use 50-ml attachment for repeater pipet for plating cells and for adding medium to
dilution plates. For the 50-ml repeater pipet to fit, the cell suspension and medium need
to be in a 250-ml Stericup flask.
4. Prewarm complete 2× MEM medium at 37°C and heat 3% Seaplaque in microwave,
and then leave in 57°C water bath until ready to use.
5. Make virus dilutions by adding 150 μl of virus to −1 dilutions for a total of 1.5 ml,
and add 15 μl to −2 dilutions for a total of 1.515 ml.











Figure 15K.2.7 Schematic of the biosafety hood setup. Efficient organization of the biosafety
hood minimizes spills and increases speed of the assay without compromising precision.
7. Add 500 μl of a given dilution to two wells each for duplicate wells.
8. Rock for 1 hr at room temperature.
9. Mix prewarmed (37°C) 2× MEM and warm (37° to 42°C) 3% (w/v) Seaplaque
agarose together in 1:1 ratio (add medium first and then add Seaplaque from the
57°C water bath so that it cools off).
The Seaplaque/2×MEM solution should be prepared immediately before use.
10. Aspirate off virus and add 2 ml of SeaPlaque/2× MEM to each well.
11. Incubate at 37°C for 48 hr.
Overlay for plaque assay
12. Mix 3 ml of Neutral Red with 100 ml PBS. Equilibrate to 37°C before use.
13. Overlay 2 ml of neutral red/PBS mixture per well.
Add the neutral red using the 50-ml repeater pipet.
14. Incubate at 37°C for 1 to 2 hr.
15. Aspirate off neutral red/PBS mixture.
16. Count plaques and calculate titer.
When performing each dilution in duplicate (i.e., 1 ml of a given dilution is analyzed),
add together the number of plaques from each of the two wells times the dilution factor
to equal the titer.
ALTERNATE
PROTOCOL 4
MEASURING MNV GENOME TITERS BY RT-qPCR
The determination of MNV levels can be achieved through amplification of viral nucleic
acid (RNA) by reverse transcription quantitative polymerase chain reaction (RT-qPCR).
This technique produces high enough concentrations of nucleic acid for detection and
quantification by fluorescence. In general, this technique relies on purification of viral
RNA, an initial synthesis of cDNA (complementary or copy DNA) by the enzyme reverse
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that cDNA coupled to real-time detection of amplification levels via readouts of fluo-
rescence. Reverse transcription can be performed as either a single reaction for cDNA
synthesis or coupled to qPCR.
In this protocol, we discuss a one-step RT-qPCR reaction for MNV-1 amplification
modified from previously published work (Taube et al., 2009), providing a reliable
determination of viral RNA levels. The conditions mentioned in this protocol were
optimized for use in the BioRad CFX96 Touch qPCR instrument, and provide analytical
sensitivity, analytical specificity, reproducibility, and repeatability, thus making them
suitable for publication following MIQE guidelines (Bustin et al., 2009). It is advised
that conditions be optimized for alternative instruments, as variations in results from
instrument to instrument can occur (technical replicate examination). If RNA quality is
optimal, and no DNA contamination is present, efficient amplification of MNV-1 from a




RNase Away reagent (Life Technologies/Ambion, cat. no. 10328-011)
Viral RNA extraction kit (e.g., Qiagen QiaAmp Viral RNA Kit, cat. no. 52906),
RNA extraction kit (e.g., Qiagen RNeasy Mini kit, cat. no. 74104), or
Trizol reagent (Life Technologies, cat. no. 15596026)
Nuclease-free H2O (APPENDIX 2A or purchase, e.g., from Invitrogen)
Ambion Turbo DNA-free DNase (Life Technologies, cat. no. AM1907) and Turbo
DNA-free buffer
Ambion Turbo DNA-free DNase Inactivation Reagent
Amplification kit: BioRad iScript One-step RT-PCR kit for Probe (cat. no.
170-88940) or BioRad iTaq Universal Probes One-Step kit (cat. no. 172-5140)
Primers: both primers bind in ORF1 of the MNV-1 genome.
Forward primer (5′ → 3′): GTGCGCAACACAGAGAAACG (HPLC
purified)
Reverse primer (5′ →3′): CGGGCTGAGCTTCCTGC (HPLC purified)
Probe (5′ →3′): [6-FAM]-CTAGTGTCTCCTTTGGAGCACCTA-[BHQ1] (HPLC
purified): probe is modified at the 5′-end with a fluorescein amidite molecule
(FAM), and at the 3′-end with the non-fluorescent molecule Black Hole
Quencher 1 (BHQ1)
Unknown sample RNAs
Plasmid containing the MNV-1 genome (for standard preparation)
Microcentrifuges (one designated for RNA work and one for DNA/plasmid work)
96-well PCR plates (Hard-Shell PCR plates 96-well white shell/clear well; BioRad,
cat. no. HSP9601)
Optical film (Microseal ‘B’ seal, BioRad, cat. no. MSB1001)
Two sets of pipettors (one for RNA handling and one for plasmid handling)
Nuclease-free 1.5-ml tubes
BioRad CFX96Touch qPCR machine
Viral RNA extraction
1. Prepare the area for RNA extraction by thoroughly cleaning it once with a 10%
bleach solution, followed by spraying it with 70% ethanol, and lastly by wiping it
twice with RNase Away.
This will help remove and/or minimize the presence of ribonucleases and DNA contami-
nation in the area. Animal RNA
Viruses
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Also wipe your gloved hands with RNase Away often, and change gloves every time you
touch surfaces that have not been cleaned. This step is crucial for obtaining high-quality
RNA, which is needed for successful downstream applications. Use of an “RNA-work-
only” designated area is advisable.
2. Carefully wipe the RNA-extraction pipettors with RNase Away. Make sure to also
pipet a full volume of RNase Away into the pipettors, without a tip, so that it can
decontaminate any potential RNases and DNA inside the pipettor barrel.
RNA-extraction pipettors should be soaked overnight in RNase Away periodically. DO
NOT use RNase Away on gaskets, seals, aluminum, or soft metals.
3. Extract viral RNA from virus-containing samples (e.g., virus-containing lysates or
homogenized tissues) using an appropriate method according to the manufacturer’s
protocol.
If using the QIAamp Viral RNA Kit, be sure to use the “spin column method” with an
“RNA-only” microcentrifuge. A vacuum manifold may be used only if one is sure that
the device has not been utilized to isolate plasmid DNA, as cross-over contamination can
occur. If cellular RNA (from virus-infected cells) is to be extracted, use of the RNeasy
Mini kit from Qiagen has provided great RNA yields and quality. If isolating RNA via
the Trizol method, make sure to perform an RNA cleanup using silica membrane-based
columns, to remove any phenol contaminants.
4. Perform an RNA cleanup step, in case any plasmid or DNA contamination (however
minimal) has occurred in the elution step. Do this using Ambion Turbo DNA-free
DNase as follows:
a. After the elution of the RNA, add sufficient amount of 10× Turbo DNA-free
buffer for a final 1× concentration in a volume containing 1 μl of Turbo DNase.
b. Incubate this solution at 37°C for 25 to 30 min.
c. Add Ambion Turbo DNA-free DNase Inactivation Reagent (same volume you
add of 10× buffer plus enzyme and water), and vortex several times to keep it
dispersed in solution.
d. Incubate for 5 min at room temperature.
e. Centrifuge at full speed to pellet inactivation reagent.
f. Pipet up almost the whole volume of sample you had originally (make sure to
pipet up about 5 μl less than what you had originally) to avoid carryover of the
inactivation reagent.
IMPORTANT NOTE: Inactivation reagent WILL inhibit your qPCR reactions.
g. Proceed with RT-qPCR.
This step is performed because of the use of plasmid DNA containing the MNV-1 amplicon
as a potential source of contamination. Cleanup could alternatively be performed as an
“on-column” DNase treatment, but this protocol has not been proven successful in
completely removing contaminating DNA.
5. To ensure RNA stability and integrity, prepare aliquots and freeze at −80°C.
Addition of RNase inhibitors is also a way of ensuring RNA stability. However, if using the
commercially available kits or reagents mentioned in this protocol, and maintaining an
RNase-free environment by using and “RNA-only” work zone/gloves and cleaning with
RNase Away, RNases are inactivated due to highly denaturing conditions and should not
affect your extraction significantly. Also, not all commercially available RNase inhibitors
are compatible with RT-qPCR. For this protocol, it is not necessary to add an RNase
inhibitor, but the reader might do so as long as it is verified that subsequent amplifications
by RT-qPCR are efficient.
If the RNA is isolated from infected cells, you can measure its quantity and estimate
its purity/integrity via spectrophotometry, making sure you measure absorbance at 260
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Table 15K.2.5 Master Mix for RT-qPCRa
Component Initial concentration Volume/reaction (1× final) Master mix (96-well) × 96 samples
2× master mix 2× 10 μl 980 μl
Forward primer 10 μM 0.1 μl 9.8 μl
Reverse primer 10 μM 0.1 μl 9.8 μl
Probe 10 μM 0.25 μl 24.5 μl
RT 50× 0.4 μl 39.2 μl
Nuclease-free H2O — 4.15 μl 406.7 μl
Template — 5 μl —
Total — 20 μl 1470 μl
aThe volumes and components outlined here are found in the BioRad iScript OneStep RT-PCR kit for Probe.
isolated from cell-free material with the use of a kit and carrier RNA (e.g., Qiagen kits),
spectrophotometric readings will only be useful for determining 260/280 ratios, as the
amount of carrier RNA will in most cases exceed the amount of viral RNA present, and
does not provide a very accurate measurement of viral RNA concentration.
Performing RT-qPCR
This reaction was optimized for the BioRad CFX96Touch qPCR machine using the
primer matrix and temperature gradient methods to provide the optimal conditions for
the highest primer and probe combinations. It results in the highest efficiency reaction
with both optimal Cq and fluorescence intensity.
6. Plan the plate arrangement according to the number of samples to be assayed, always
including the standards, a no-template control, a positive control, and a no-RT control
as part of the sample group.
Each sample should be run in duplicate, but preferably in triplicate, to observe for
pipetting error.
7. Thaw reaction components on ice, mix them thoroughly, and briefly centrifuge them
to collect the volume at the bottom of the tubes.
Light-sensitive components (e.g., probe) should be protected from light.
8. Set up the RT-qPCR reaction by calculating the amount of reagents needed. Reaction
volume should be 20 μl final.
If another volume is made, concentration of both primers should be 0.05 μM final and
probe concentration should be 0.125 μM final.
All steps may be performed at room temperature if a vendor-supplied mix is used, as
most reaction mixes contain a hot-start Taq polymerase and reagents that are stable at
room temperature for several hours. However, reactions can be assembled on ice when
degradation is suspected.
Plates may be made several days in advance and stored at 4°C until the reactions are
ready to run. This does not cause a substantial decline in the performance of the PCR
enzyme. Advance preparation of plates is not recommended if qPCR mixes are not from
commercial sources (i.e., they are home-made), as these mixes lack additives present
in the commercial mixes that confer stability to the reaction components. Whenever
possible, fresh reactions should be run.
9. Prepare a master mix in a 1.5 ml nuclease-free tube (see Table 15K.2.5), containing
each reagent but no template, for at least 1.5 to 2 samples more than what you have
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This will compensate for pipetting errors.
10. Mix thoroughly to ensure homogeneity and dispense 15-μl aliquots into the required
wells of a 96-well plate. Use good pipetting technique to ensure precision and
accuracy.
11. Dispense 5 μl of each unknown sample RNA into the required well, using RNA-only
pipettors.
The no-template control should have master mix and nuclease-free water. For the no-RT
control, do not add RT enzyme, and make up the volume with nuclease-free water.
Use equal volume for samples isolated from cell-free materials. For infected cell RNA,
measure RNA concentration (Gallagher, 2011) and load equal amounts of RNA, prefer-
ably in equal volume.
Dispense the standards last, after performing at least six 10-fold serial dilutions of the
plasmids (step 13).
It is generally not advisable to use DNA as a standard for absolute quantification of RNA
because there is no control for the efficiency of the reverse-transcription step. However,
if it is not possible to in vitro transcribe RNA, the use of plasmid DNA with the template
of interest is fine. Be sure to linearize the plasmid prior to amplification, as super-coiled
DNA is not as efficiently amplified as linear DNA (template site is not as accessible to
primers if DNA is super-coiled).
12. Make serial dilutions of standards.
To make serial dilutions of your standards, you first have to know the molar concentration
of your plasmid. This way you can calculate copy numbers to be translated into genome
copies later on.
a. Determine the concentration of the linearized plasmid by spectrophotometry
and convert the readout to g per liter.
b. Calculate the formula weight (FW) for your plasmid as follows:
Plasmid size (in base pairs) × 662 grams/mol (average weight of a nucleotide
pair).
c. Calculate the molar concentration of your linearized plasmid (M):
M = mol/liter = (mass in g/FW)/1 liter
d. Determine copy number per microliter based on molar concentration:
1 M is about 6.02 × 1023 copies.
13. Make 10-fold serial dilutions of the plasmid in nuclease-free water and add 5 μl to
the dispensed reaction mix. Make note of how many copies of plasmid each sample
standard contains.
Pipetting accuracy is crucial in this step for correct analyses of samples after the PCR
run.
14. Cover the plate with the optical adhesive cover and then briefly centrifuge the plate
to get contents to the bottoms of the wells, and to remove any air bubbles.
15. Load the plate into the instrument and run the RT-qPCR reaction using the following
thermal cycler program:
1 cycle: 10 min 50°C (reverse transcription)
1 cycle: 5 min 95°C (initial denaturation)
40 cycles: 10 sec 94°C (denaturation)
30 sec 60°C (annealing).




































FAM E  100 1% R^2  0.997 Slope  3.319 y-int  38.807
Figure 15K.2.8 RT-qPCR results for standard curve amplification of a plasmid containing the MNV-1 ORF1 region. Eight
10-fold serial dilutions were made of a plasmid containing the MNV-1 ORF1 region and were run as duplicates in an
RT-qPCR experiment with BioRad reagents and the BioRad CFX96 Touch instrument. (A) Amplification plot of MNV-1
standards. (B) Automatic standard curve generated by the BioRad CFX96 Touch instrument. Note that the slope of the
curve has a value of –3.319, which corresponds to the approximate 100.1% amplification efficiency of the primers binding
to its target template and allows for an exact doubling of nucleic acid quantities with each cycle of amplification.
Make sure that your standard curve has a correlation coefficient (R2) higher than 0.98
and shows a slope close to -3.3, which ensures that your primers have close to 100%
efficiency for amplification (you have double the original amount of template as each
cycle progresses). Figure 15K.2.8 shows an example of a standard curve obtained for
MNV-1 standards. The most dilute standard within the linear range of the standard curve
is 2 genome copies (Fig. 15K.2.8B). Thus, the reliable limit of detection for this particular
protocol of MNV-1 amplification is 2 genome copies.
17. To calculate the genome copies per ml of virus in your preparation, multiply the
genome copies per well calculated in your RT-qPCR run by the dilution factor
obtained after the RNA extraction experiment and according to the sample volume
loaded in the reaction.
BASIC
PROTOCOL 6
STRAND-SPECIFIC QUANTIFICATION OF MNV-1 RNA
The presence of negative-strand viral RNA during any positive-strand RNA virus infec-
tion is an indicator of active replication. The specific detection and quantification of the
(-) strand viral RNA is therefore an important tool for the study of molecular mechanism
of viral RNA replication. However, due to the fact that both most reverse transcriptase
enzymes produce “self-primed” and “false-primed” cDNA, and the presence of both
(+) and (-) strand during virus replication, absolute quantification of either strand is not
possible by regular RT-qPCR. Several modifications can overcome these problems—
including a thermo-stable reverse transcriptase and use of a non-viral tag sequence in
the reverse transcription primer, which is then used for specific amplification of tagged
cDNA—and make the assay strand-specific (Timofeeva and Skrypina, 2001; Piche and
Schernthaner, 2003; Stahlberg et al., 2004; Tuiskunen et al., 2010). The protocol de-
scribed herein is based on a recently published method that utilizes these modifications
for the detection and absolute quantification of MNV-1 positive and negative strand
(Vashist et al., 2012a,b). The Basic Protocol describes all the steps of strand-specific
RT-qPCR (RNA-primer annealing, reverse transcription, and qPCR). During reverse
transcription, a strand-specific oligonucleotide primer containing sequence complemen-
tary to the strand being detected is annealed with the RNA, and cDNA is synthesized
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Table 15K.2.6 Primers Used for RT-qPCR
RNA Name Sequence 5′-3′ Positiona
Gpos RT TposGpos CGGGAAGGCGACTGGAGTGCCCAAACATCTTTCCCTTGTTCb 1760-1779
qPCR - F Tpos CGGGAAGGCGACTGGAGTGCC Nonviral
qPCR -R Gneg TGGACAACGTGGTGAAGGAT 1678-1697
Gneg RT TnegGneg GGCCGTCATGGTGGCGAATAATGGACAACGTGGTGAAGGAT 1678-1697
qPCR - F Tneg GGCCGTCATGGTGGCGAATAA Nonviral
qPCR -R Gpos CAAACATCTTTCCCTTGTTC 1760-1779
aThe genome positions are with reference to the MNV-1.CW-1 genome RNA sequence. The standard RNAs were designed to include the neighboring
RNA secondary structure complexity to imitate the actual RNA.
bThe 5′ end of the forward primer (underlined sequence) is T7 promoter. T7 polymerase needs this sequence to start RNA synthesis.
qPCR, and the absolute number of RNA copies is determined by extrapolation from
a standard curve. The standard curve–plotting function is available in most instrument
software. If it is not, graphing software may be used instead (e.g., Microsoft Excel or
GraphPad Prism). This qPCR protocol can reproducibly detect down to 50 copies per
well.
Materials
Total RNA isolated from infected cells (see “Viral RNA extraction” steps in
Alternate Protocol 4)
Control in vitro–transcribed RNA (Support Protocol 4)
10 μM RT primer (Table 15K.2.6)
10 mM dNTP mix (APPENDIX 2A)
5 × first-strand synthesis buffer (Life Technologies, supplied with SuperScript III)
M DTT (Life Technologies, supplied with SuperScript III)
40 U/μl RNaseOUT (Life Technologies)
SuperScript III (SS-III) reverse transcriptase (Life Technologies, cat. no.
18080-044) and 5× RT buffer
Nuclease-free H2O (APPENDIX 2A; or purchase, e.g., from Life Technologies)
10 μM PCR primers (Table 15K.2.6)





qPCR thermal cycler (Life Technologies)
Thermosealer (Life Technologies)
Anneal the primer to the RNA
1. In a PCR tube, mix the strand-specific RT primer—TposGpos, for positive-sense
RNA or TnegGneg for negative-sense RNA—total RNA, and dNTP mix by adding
the following to a microcentrifuge tube:
100 ng total RNA or serially diluted control standard (in vitro–transcribed)
RNA
0.2 μl 10 μM RT primer
1 μl 10 mM dNTP mix
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2. Heat to 65°C and snap freeze on ice.
Heating the mix removes any secondary structures in the RNA and allows the primer to
begin to anneal.
cDNA synthesis
3. Microcentrifuge the sample for 10 sec at 1000 × g to collect the condensate at the
bottom of the tube.
4. Add 9 μl of RT mix per reaction, prepared as follows:
4 μl 5× first-strand synthesis buffer
1 μl 0.1 mM DTT
0.8 μl RNaseOUT
0.2 μl SuperScript III reverse transcriptase
Nuclease-free H2O to 9 μl.
A master mix can be prepared for more than one reaction and kept on ice. When using
this approach, it is advisable to include at least an extra 10% to 15% in the final volume
of the master mix to allow for pipetting errors. Once prepared, master mix should be kept
on ice.
5. Mix the contents of PCR tubes and incubate for 30 min at 55°C.
6. Inactivate the RT enzyme by heating the PCR tubes to 95°C for 5 min.
7. Centrifuge the sample for 10 sec at 1000 × g to collect the condensate at the bottom
of the tube.
SuperScript III RT is a thermostable enzyme and has high processivity at 55°C. Use of a
thermostable enzyme as well as a calibrated amount of RT primer and time of reaction
allows minimum synthesis of false-primed cDNA.
It is important to centrifuge the tubes after heating to recover evaporated solution to
accurately determine the RNA quantity.
Amplify the cDNA by qPCR and analyze data
8. Mix the following:
For (+) strand RNA detection
0.25 μl each qPCR primer (Tpos and Gneg—Table 15K.2.6)
10 μl 2× MESA Blue Mastermix
Nuclease-free water to 18 μl.
For (−) strand RNA detection
0.25 μl each qPCR primer (Tneg and Gpos—Table 15K.2.6)
10 μl 2× MESA Blue Mastermix
Nuclease-free water to 18 μl.
Use of the tag primer gives specificity to the PCR reaction. Hence, any false-primed
cDNA without the tagged RT primer would not be amplified during the PCR reaction.
For each reaction, a master mix can be prepared for more than one reaction and kept on
ice. When using this approach, it is advisable to include at least an extra 10% to 15% in
the final volume of the master mix to allow for pipetting errors. Once prepared, master
mix should be kept on ice.
9. Transfer 18 μl of the PCR mix from the above step to wells of a 96-well qPCR plate.




































































































Figure 15K.2.9 A typical layout of the qPCR plate is shown. Rows 1 to 6 contain master mix for detection of positive-
sense RNA and Rows 7 to 12 contains master mix for negative-sense RNA. Rows 1 to 3 and 4 to 6 contain samples
from mentioned time points of growth curve while rows 4 to 6 and 10 to 12 contain samples for standard curve and
no-template control.
It is important to dilute the standard RNA in the presence of a carrier RNA. We typically
use 20 ng/μl yeast RNA.
11. Add 2 μl cDNA samples (step 7) to respective wells.
12. Seal the plate with a thermosealer, making sure that all the wells are sealed, partic-
ularly the corners of the plate.
13. Place the plate in the plate holder of the qPCR machine.
14. Perform qPCR using the following thermal cycling parameters.
Data collection for the detection of PCR amplification is performed during the annealing
and extension steps of the PCR cycle, while for the melt curve stage the data is collected
at the ramp stage between annealing and dissociation.
a. PCR program:
1 cycle: 10 min 95°C (activates the polymerase)
50 cycles: 15 sec 95°C (denaturation)
20 sec 58°C (annealing)
20 sec 72°C (extension).
b. Melting curve analysis:
15 sec 95°C
20 sec 58°C
Increase from 58° to 95°C at a 0.05°C/in temperature ramping rate
20 sec 95°C.
A typical layout of the plate for a growth curve using time points 0 hr, 6 hr, 12 hr, and
24 hr, including standard curve and no template control, is presented in Figure 15K.2.9.
15. Analyze the qPCR data by extrapolating from the standard curve.
The standard curve plotting function is available on most software provided with qPCR
machines. If such software is not provided, graphing software may be used instead by
plotting Ct Values versus log10 copy number of the control standard RNA.
It is very important to analyze the melting curve before analyzing the amplification data.
The melting point (Tm) of all the PCR products should be identical. If the Tm deviates,
it is indicative of either primer-dimer formation or the generation of nonspecific PCR
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Table 15K.2.7 Primers Used for Generation of Standard RNAs
Standard RNA Name Sequence 5′-3′a Positionb
Gpos7 Gpos-F GCGTAATACGACTCACTATAGGGCTTTTGGCCTCACCTCTG 1085-1104
Gpos-R CCAAGATGAAATTGATGTGGCTGTAATCGGGCC 1954-1986
Gneg7 Gneg-F GCGTAATACGACTCACTATAGGGTGCCAAGATGAAATTGATG 1970-1990
Gneg-R GCTTTTGGCCTCACCTCTG 1086-1104
aThe 5′ end of the forward primer (underlined sequence) is T7 promoter. T7 polymerase needs this sequence to start RNA synthesis.
bThe genome positions are with reference to the MNV-1.CW-1 genome RNA sequence. The standard RNAs were designed to include the neighboring
RNA secondary structure complexity to imitate the actual RNA.
SUPPORT
PROTOCOL 4
GENERATION OF STANDARD RNAs REPRESENTING MNV-1 (+) AND (−)
SENSE GENOMIC RNAs
For the absolute quantification of RNA copies in a sample, it is important to make a
standard curve using a known number of copies of control standard RNA representing the
amplified region. This protocol describes a method for the preparation of RNA standards
representing the positive and negative strands of the MNV-1 genomic RNA. The use of
RNA instead of DNA for the generation of a standard curve also allows for control at the
RT step. The control standard RNA can be synthesized by in vitro transcription reaction
as described below. Several commercially available in vitro transcription kits could also
be used to prepare the RNA.
Materials
100 ng/μl plasmid DNA template (pT7:MNV1 3′Rz, available without MTA from
Dr. Ian Goodfellow, Cambridge University)
KOD polymerase kit (Merck)
10 mM dNTP mix (APPENDIX 2A)
10 μM PCR primers (Table 15K.2.7)
1% agarose TBE gel (Voytas, 2000)
0.5 × TBE buffer (APPENDIX 2A)
DNA ladder (e.g., GeneRuler 1-kb Plus, Fermentas)
PCR purification kit (GE Healthcare)
0.4 M Tris·Cl, pH 8.0 (APPENDIX 2A)







Pyrophosphatase (New England Biolabs, cat. no. M2403L)
40 U/μl RNaseOUT (Life Technologies)
Nuclease-free water
T7 RNA polymerase (Promega, cat. no. P2074)
Nuclease-free H2O (APPENDIX 2A, or purchase, e.g., from Promega or NEB)
2 U/μl DNase I (RNase-free, Life Technologies)
3 M sodium acetate, pH 5.2 (APPENDIX 2A)
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Additional reagents and equipment for agarose gel electrophoresis (Voytas, 2000)
and SDS-PAGE (APPENDIX 3M)
Generate PCR product with T7 promoter at the 5′ end
1. Generate Gpositive and Gnegative PCR products using the KOD polymerase kit
according to the manufacturer’s instructions along with pT7:MNV1 3′Rz as template
and PCR primers detailed in Table 15K.2.7.
pT7:MNV1 3′Rz is the full length infectious clone of MNV-1.CW-1 (Chaudhry et al.,
2007).
2. Run the PCR product on a 1% agarose gel (Voytas, 2000) in TBE buffer along with
a DNA ladder and purify the DNA using a commercially available gel purification
kit.
Generate RNA using in vitro transcription
3. Mix the following in the order as described below:
It is important to maintain the order of addition of the components in this reaction and
to mix well after adding each component. A master mix lacking the template DNA can
be prepared, and then aliquotted to facilitate the synthesis of several transcripts at once.
Keep all reagents on ice once thawed. A commercially available kit (e.g., Promega,
P1440) could also be used for in vitro transcription.
10 μl 0.4 M Tris·Cl, pH 8.0
10 μl 320 mM magnesium acetate
10 μl 400 mM DTT
10 μl 20 mM spermidine
7.5 μl 100 mM ATP
7.5 μl 100 mM GTP
7.5 μl 100 mM CTP
7.5 μl 100 mM UTP
2 μl pyrophosphatase
5 μl 40 U/μl RNaseOUT (Life Technologies, cat. no. 10777-019)
10 μl PCR product from step 2 (>200 ng)
10 μl T7 RNA polymerase (Promega, cat. no. P2074)
Nuclease-free H2O to 100 μl.
4. Mix well and incubate 2 to 4 hr at 37°C.
5. Run 2 μl on denaturing 5% SDS-PAGE gel (BioRad Mini Protean gel or similar) to
check the yield and purity of the RNA (APPENDIX 3M).
6. Add 2 μl of 2 U/μl DNase I and continue the incubation in 37°C water bath for
another 30 min.
7. Add 100 μl nuclease-free water.
8. Add 20 μl 0.3 M sodium acetate to each sample and mix well.
9. Extract each sample with 200 μl of 25:24:1 phenol/chloroform/isoamyl alcohol.
Carefully transfer only the aqueous phase from each tube to a new 1.5-ml micro-
centrifuge tube.
CAUTION: Phenol is a neurotoxin. Local safety regulations for its use and disposal
should be followed.
10. Add 500 μl of 100% ethanol and mix well. Microcentrifuge each sample 15 min at
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11. Carefully remove the liquid from the small white pellets and add 400 μl of 75%
ethanol to each tube. Centrifuge 5 min at 13,000 × g.
12. Carefully remove all the liquid from the pellets. Dry the pellets at room temperature
and dissolve each in 100 μl nuclease-free water.
Excessive drying will prevent the RNA from dissolving in water.
13. Quantitate the RNA using a Nanodrop UV spectrophotometer.
14. Convert RNA concentration to copy number.
Tools and scientific calculators are widely available to do this calculation (see Internet
Resources). To calculate manually:
a. Calculate the concentration of RNA using the formula: 1 A260 = 40 μg/ml.
b. Calculate the molecular weight of the RNA molecule using the formula: mol. wt. =
(no. of nucleotides × 320.5) + 159.
320.5 is the average molecular weight of the nucleotides and 159 is the molecular weight
of a 5′ triphosphate.
c. Calculate copy number using the formula: Copy number/μl = 6.02 × 1023 × [RNA]
in μg/ml × 10−9/(mol. wt. in g/mol).
15. Aliquot and store the samples at −80°C at 1010 copies/μl.
BASIC
PROTOCOL 7
siRNA TRANSFECTION OF BV-2 CELLS USING NEON TRANSFECTION
SYSTEM
Understanding of the role of host-cell genes during MNV infection is facilitated by
manipulating these genes in tissue culture. siRNAs designed against specific genes are a
powerful tool that can be delivered into cells to down-regulate expression of their target
mRNA. Transfecting nucleic acid into cells can be achieved by a variety of mechanisms,
including chemical, mechanical, and electrical delivery. Electroporation of nucleic acid
into cells was first proposed in 1982 (Neumann et al., 1982), and has since developed
into a highly efficient research tool. To overcome the initial problems of low cell
viability, low transfection rates, and complicated protocols, Kim et al. (2008) produced
a novel electroporation system using a capillary and wire-type electrode. This was
initially developed as the Microporator (MP-100) by Digital Bio. This has since been
optimized, and is now marketed by Life Technologies as the Neon transfection system.
In cell culture, MNV infects cells of the macrophage lineage, such as BV-2 cells (murine
microglial cell line) and RAW 264.7 cells (murine leukemic monocyte macrophage cell
line). siRNA transfection of BV-2 cells via the Neon transfection system (Life Tech-
nologies) is efficient and has been successfully used to study the role of target host genes
during MNV infection (Vashist et al., 2012a,b). This protocol describes the methods used
to transfect large numbers of cells with a specific siRNA, often resulting in significant
reduction in the target protein within 18 hr of transfection. However, it is recommended
to analyze target gene expression at various time points between 12 and 48 hr post
transfection to determine the optimum time for maximal reduction in gene expression.
Materials
Confluent flask(s) of BV-2 cells (Blasi et al., 1990), passaged 24 hr prior to start of
protocol to ensure actively growing cells
Phosphate-buffered saline (PBS), pH 7.4, sterile (e.g., Life Technologies, cat.
no.10010-023)
BV-2 medium: Dulbecco’s Modified Eagle Medium (DMEM) supplemented with
10% fetal bovine serum (FBS), 2 mM L-glutamine, and 1×
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siRNAs: directed against the target and a control housekeeping gene (e.g., GAPDH)
NEON 100 μl kit; (Life Technologies, cat. no. MPK10096; (contains Buffers E and
R, gold tips, and tip holder)
NEON pipet (Life Technologies, cat. no. MPP100)
6-well cell culture dishes
15-ml sterile conical tubes (e.g., BD Falcon)
Additional reagents and equipment for basic cell culture techniques including
trypsinization and cell counting (Phelan, 2006), and western blotting (Gallagher
et al., 2008)
1. Aspirate the medium from the BV-2 cells, wash the monolayer with PBS, and detach
the cells using commercial trypsin (all techniques described in Phelan, 2006).
A total of 7.2 × 106 live cells will be required per transfection.
2. Neutralize trypsin using prewarmed BV-2 medium, then remove the suspended cells
from the culture flask and centrifuge in a tabletop centrifuge 5 min at 1200 × g,
room temperature. Remove the supernatant and resuspend the cells in 10 ml of BV-2
medium.
3. Determine the concentration of live cells in presence of trypan blue (Phelan, 2006).
4. Transfer 7.2 × 106 live cells to a sterile microcentrifuge tube for each transfection.
Centrifuge cells 2 min at 1200 × g, room temperature, in a tabletop centrifuge,
remove supernatant, then resuspend in 1 ml PBS.
It is advisable to leave cells in growth medium until immediately before washing with
PBS. Typically, cells can be aliquotted into sterile microcentrifuge tubes and kept at room
temperature until required. The time period that cells are exposed to PBS and Buffer R
(see step 8) should be kept to an absolute minimum.
5. Place the electrode of the Neon system inside the tissue culture hood where the
transfection is to take place and place a Neon tube (tip holder) in the electrode. Add
3 ml Buffer E to this Neon tube.
Each Neon tube with Buffer E can be used for up to 10 transfections without contamina-
tion.
6. Set the instrument parameters for the following conditions: voltage, 1700; width,
10 msec; pulse, 3.
7. Label 6-well plates (3 wells per sample) and 15-ml conical tubes. Add 9 ml BV-2
medium (without antibiotics) to each conical tube.
8. Centrifuge the 7.2 × 106 cells suspended in PBS (from step 4) 2 min at 1200 × g,
room temperature, in tabletop centrifuge. Remove the supernatant, then resuspend
the cells in 120 μl Buffer R to achieve the desired cell concentration of 6.6 × 106
cells/100 μl for each transfection.
It is advisable to use 20% extra cells in 20% extra Buffer R as described above to avoid
bubble formation during aspiration of cells by the Neon tip. The amount of siRNA should
thus be altered accordingly.
9. Add the required amount of target siRNA to 7.2 × 106 cells in Buffer R, mixing
carefully and thoroughly.
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Figure 15K.2.10 siRNA-mediated reduction in protein expression as demonstrated by western
blotting. siRNA targeting the host cell gene DDX3 and control siRNA were transfected into BV-2
using the Neon transfection system. Cells were harvested at 18-, 24-, and 30-hr time points, and
protein extracted. Protein samples were then separated using SDS-PAGE and analyzed using
western blotting with anti-DDX3 and anti-GAPDH as loading controls.
10. Mix the cells slowly and gently, then aspirate 100 μl of the cell-siRNA mix into
the Neon tip using the Neon pipet. Insert this into the pipet station until a click is
heard.
IMPORTANT NOTE: It is essential to avoid any air bubble formation while setting up
the sample for electroporation. Formation of bubbles during mounting of the electrode
is common, and the process must be carefully repeated until no bubbles are present. Air
bubbles result in the generation of sparks during electroporation, and hence major cell
death.
11. Press the start button to start electroporation.
The machine will confirm successful electroporation once completed.
12. Remove the Neon pipet from the pipet station and transfer the electroporated cells
to the 9 ml of medium in the conical tube (pre-prepared in step 7).
13. Repeat steps 8 to 12 for the remaining samples.
NOTE: Each Neon tip can be reused up to a maximum of three times for transfection of
cell samples with the same type of siRNA.
14. Mix the electroporated cells slowly with the fresh medium and add 3 ml each to 3
wells of labeled 6-well culture dishes.
15. Incubate at 37°C with 5% CO2 until the cells form a monolayer (this can take
between 6 and18 hr). When a monolayer is formed, replace the medium with BV-2
cell medium containing antibiotics.
16. Harvest cells at predetermined time-points (between 12 and 48 hr are suggested), and
analyze protein expression of the target gene using western blotting (Fig. 15K.2.10).
Protocols for western blotting (immunoblotting) are provided in Gallagher et al. (2008).
BASIC
PROTOCOL 8
LENTIVIRAL TRANSDUCTION OF PRIMARY BONE MARROW–DERIVED
MACROPHAGES FOR MNV INFECTION
Analysis of viral replication in primary cells is an efficient way to study the interaction
of virus with its host in more physiological conditions than in transformed or immor-
talized cell lines. However, compared to established cell lines, it is difficult to obtain
a homogenous population of primary cells in sufficient number for experimentation. It
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transfection. Bone marrow–derived macrophages obtained through culturing bone mar-
row progenitor cells with macrophage colony-stimulating factor (M-CSF) (Stanley et al.,
1983) is a good solution for securing a large number of primary cells for MNV infection;
transduction of these cells with lentivirus is an efficient way to over-express or down-
regulate a gene of interest. In this protocol, bone marrow cells are harvested and cultured
in medium containing M-CSF to generate bone marrow–derived macrophages (Support
Protocol 5), and lentiviruses are produced in 293T cells by transfecting lentiviral vector
with packaging and pseudotyping vectors (Support Protocol 6). Prepared lentiviruses
are used to transduce adherent cells from the bone marrow progenitors twice, on Days
4 and 5 of culture. On Day 7, transduced bone marrow-derived macrophages are har-
vested for further selection or subsequent assays. This procedure optimally yields 5–10
× 106 macrophages, of which > 90% express the gene of interest or the cassette for
down-regulating the gene of interest.
Materials
Day 4 bone marrow culture for the derivation of macrophages (Support Protocol 5)
Macrophage complete medium (see recipe)
Lentiviral vectors (Support Protocol 6)
Selection antibiotic, e.g., 1 μg/ml puromycin in culture medium
PBS/EDTA solution (e.g., Sigma, cat. no. E8008)
10-cm culture plates
Sterile cell lifter (e.g., Fisher Scientific, cat. no. 08 100 240)
50-ml conical tubes (e.g., BD Falcon)
6- or 24-well culture plates
Additional reagents and equipment for basic cell culture techniques including
trypsinization and cell counting (Phelan, 2006)
1. On Day 4 of bone marrow culture (Support Protocol 5), gently swirl the plate a couple
of times to detach any loosely bound materials and remove the unbound with culture
medium.
Typically, 50% to 60% confluency is expected on Day 4.
2. Add 5 ml of fresh macrophage complete medium and half of the prepared lentivirus
(i.e., 10 ml) per 10-cm plate.
Replacing macrophage complete medium help cells stay healthy.
Addition of polybrene does not enhance the transduction of vesicular stomatitis virus G
protein (VSV-G) pseudotyped lentiviral vectors.
3. On Day 5, discard the culture medium with lentivirus and add 5 ml of fresh
macrophage complete medium and the rest of the prepared lentivirus (i.e.,
10 ml) per 10-cm plate.
4. Optional: Select transduced cells by expression of reporter gene (e.g., green flu-
orescent protein from pCDH-MCS-T2A-copGFP-MSCV) or drug resistance gene
(e.g., puromycin N-acetyltransferase from pLKO.1 puro). For the drug selection
of transduced cells, add drug (e.g., 1 μg/ml puromycin) for 3 days, on Days 6
through 9.
5. On Day 7 (or on Day 9 for drug-selected cells), remove unbound cells and discard
culture medium. Add 5 ml of cold PBS to the remaining adherent cells, swirl gently to
remove loosely bound cell debris, discard the PBS, and add 5 ml of cold PBS/EDTA
per each plate. Incubate at 4°C for 10 min.
For transduced but unselected cells, a confluency of 90% to 100% is expected, while 70%
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6. Scrape off the cells with cell lifter, add 5 ml of cold macrophage complete medium
per plate, resuspend the cells by pipetting up and down, and transfer them to a 50-ml
conical tube.
Keep macrophages cold to minimize loss due to their adherence to the tube.
7. Centrifuge 5 min at 300 × g, 4°C.
8. Discard supernatant, resuspend the cells in 5 to 10 ml macrophage complete medium,
and count the number of cells (Phelan, 2006).
The volume of the resuspension medium needs to be determined based on subsequent
assays. The typical yield at this stage is 5–10 × 106 transduced macrophages for the
unselected and 1–3 × 106 transduced macrophages for the drug-selected cells per 10-cm
plate.
9. At this time, replate macrophages for further experimentation.
Usually, the cells are plated at 0.5–1 × 105 cells/well in 1 ml of macrophage complete
medium for a 24-well tissue culture plate or at 2.5–5 × 105 cells/well in 2 ml of macrophage
complete medium for a 6-well tissue culture plate.
Three days after seeding, macrophages are ready to be used for MNV infection (for example
as described in Basic Protocol 1) and subsequent assays (e.g., western blot or quantitative
PCR to measure the over-expression or down-regulation of genes of interest).
The efficiency of transduction and/or expression of gene of interest in the transduced
cells can vary significantly depending on the size of the lentiviral vector. In general, the
efficiency inversely correlates with the size of the lentivirus. For example, over 90% of
cells expressed green fluorescent protein upon transduction with lentiviruses from pCDH-
MCS-T2A-copGFP-MSCV vector itself, but only 20% to 30% of cells showed the reporter




PREPARATION OF MOUSE BONE MARROW SUSPENSION FOR
MACROPHAGE CULTURE
This protocol describes the purification of bone marrow progenitor cells from mouse hind
legs (both tibias and femurs) and differentiation into bone marrow–derived macrophages
with medium containing M-CSF.
NOTE: All protocols involving live animals must be reviewed and approved by an
Institutional Animal Care and Use Committee (IACUC) and must conform to government
regulations for the care and use of laboratory animals.
Materials
Donor mice, 6- to 12-weeks old, specific pathogen-free
70% ethanol
Phosphate-buffered saline (PBS), pH 7.4, sterile (e.g., Life Technologies, cat.
no.10010-023)
Macrophage complete medium (see recipe)
Forceps and scissors (keep in sterile container containing 70% ethanol)
100 × 15–mm petri dishes (non–tissue culture treated)
15- and 50-ml conical centrifuge tube, sterile
10- or 30-ml syringes with 26-G needles, sterile
Additional reagents and equipment for mouse euthanasia (APPENDIX 3N)
1. Euthanize a mouse according to the guidelines of the home institution (e.g.,
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euthanized mouse either by spraying sufficient 70% ethanol to cover the whole body
or by soaking the mouse in 70% ethanol. Cut out the foot, peel off skin, and cut off
the hind legs at the hip joint, keeping the tibias and femurs intact.
Dissection in clean environment (e.g., inside biosafety cabinet) is recommended to minimize
any contamination.
2. Remove excess muscle from tibias and femurs, briefly dip them in the 70% ethanol
in a Petri dish for quick sterilization, and put them in a new clean petri dish.
3. Remove the mouse carcass, clean up the biosafety cabinet, and get a new pair of
gloves and sterile equipment if necessary.
If the dissection equipment is going to be used again, make sure to clean and sterilize with
70% ethanol.
4. Prepare one 50-ml conical tube per mouse and fill up the tube with macrophage
complete medium. Load a syringe with the prepared macrophage complete medium
in the tube and attach a 26-G needle.
Alternatively, you can start with wash medium or PBS to collect bone marrow first, spin
down at 300 × g for 5 min, discard supernatant, and resuspend the cell pellet in the
macrophage complete medium.
5. Using sterile forceps and scissors, cut both ends of bones proximal to each joint and
insert needle into bone marrow cavity. Flush bone cavity with medium until color of
bone cavity changes from red to white.
It takes usually 2 to 3 ml of medium to completely flush out bone marrow from one bone.
6. Combine the bone marrows from a single mouse in a 50-ml conical tube.
7. Mix well by pipetting up and down and plate the cells into non–tissue culture treated
100 × 15–mm petri dishes. Usually, dispense 10 ml of bone marrow suspension per
petri dish and make up to 10 petri dishes per mouse.
Macrophages do not come off tissue culture–treated plasticware. Make sure to use
non–tissue culture treated petri dishes to enable replating of bone marrow-derived
macrophages.
Each petri dish of cells is transduced with a single type of lentivirus, so the number of
petri dishes of cells should match the number of lentiviruses for transduction.
Typically, bone marrow progenitor cells from a single mouse can be plated in up to 10
petri dishes to produce similar number of bone marrow-derived macrophages per dish at
the time of harvest (i.e., on Day 7).
8. Incubate the cells in 37°C, 5% CO2 incubator for 4 days.




PRODUCTION OF LENTIVIRAL VECTOR
This protocol describes the preparation of VSV-G pseudotyped lentiviruses through
the transfection of relevant plasmids into 293T cells. VSV-G is a highly stable protein
with ubiquitously expressed receptors on mammalian cells, so it enhances the structural
stability and tropism of the pseudotyped lentivirus.
Materials
293T cells (ATCC no. CRL-3216)
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Plasmids:
Pseudotyping vector encoding the G protein of vesicular stomatitis virus
(VSV-G, e.g., pMD2.G, Addgene plasmid 12259)
Lentiviral packaging vector (e.g., psPAX2, Addgene plasmid 12260)
Lentiviral vector of choice (e.g., pCDH-MCS-T2A-copGFP-MSCV, System
Biosciences CD523A-1, for the over-expression of a gene or pLKO.1
puro, Addgene plasmid 8453, for the down-regulation of a gene)
2.5 M CaCl2, sterile
2× HeBS (see recipe), sterile
Macrophage complete medium (see recipe)
10-cm tissue culture–treated dishes
15- and 50-ml conical tubes (e.g., BD Falcon)
0.45-μm filter unit
Additional reagents and equipment for basic cell culture techniques including
trypsinization and counting cells (Phelan, 2006)
CAUTION: Handling of human cell line requires special caution due to possible con-
tamination of human pathogens.
1. On the same day that the bone marrow progenitor cells are harvested (Day 0), seed
4 × 106 293T cells in a 10-cm tissue culture–treated dish with 10 ml DMEM-10.
Make as many dishes as you want to produce lentivirus and set up transduction.
The ideal cell density at the time of transfection is 60% to 70% confluency. Too few cells
or too many cells can lead to the loss of cells during the harvest and reduced yield of
lentiviruses.
2. Day 1: For each 10-cm plate of 293T cells to be transfected, prepare the following
transfection mix in a sterile 15-ml conical tube:
6.5 μg packaging vector
3.5 μg VSV-G pseudotyping vector
10 μg lentiviral vector
3. Add 100 μl of 2.5 M CaCl2 and 900 μl sterile water to the DNA mix. Mix well by
pipetting up and down.
4. To another 15-ml tube, add 1 ml of 2× HeBS. While vortexing the tube containing
2× HeBS, add the 1 ml of DNA/CaCl2 mix dropwise to the 2× HeBS tube.
Set the speed of the vortex to mix vigorously without spilling out the contents.
5. Leave the tube at room temperature for 5 to 30 min to allow the formation of fine
precipitates of DNAs for transfection.
6. While incubating, replace the medium on the 293T cells with 10 ml of fresh DMEM-
10.
The medium can be replaced as early as 3 hr before transfection.
7. Add the solution directly from the tube in step 5, containing the precipitate, in a
dropwise manner onto the cells (total 2 ml per plate), covering the whole surface of
the plate. Add drops right above the surface of the medium to minimize any impact
that can detach 293T cells from the plate. Shake the plate gently and perpendicularly
a couple of times until the medium has recovered a uniform color. Incubate the cells
in 37°C, 5% CO2 incubator for 12 to 16 hr.
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8. Aspirate the medium and add 7 ml of macrophage complete medium gently to the
transfected cells. Incubate the cells in 37°C, 5% CO2 incubator.
CAUTION: Biosafety Level 2 (BSL-2) practices are required for handling of lentivirus.
9. Twelve hr after medium change, harvest the culture medium from each plate, collect
in a 50-ml conical tube, and add 7 ml of fresh macrophage complete medium back
to the transfected cells. Incubate the cells in 37°C, 5% CO2 incubator and store the
collected medium at 4°C.
10. Repeat step 9 two more times every 12 hr and keep the collected culture medium
at 4°C throughout the collection period. Discard the transfected 293T cells after the
third harvest, according to your institutional biosafety regulations.
11. Filter the pooled culture medium (20 ml final per each transfection) using a 0.45-
μm filter unit.
The filtered culture medium containing lentivirus can be used directly or concentrated if
needed. It can be kept at 4°C for a couple of days or −80°C for a long-term storage.
Avoid freeze/thaw cycles, as they reduce the titer of lentivirus preparations.
ALTERNATE
PROTOCOL 5
LENTIVIRAL TRANSDUCTION OF MACROPHAGE CELL LINES TO
OVER-EXPRESS OR DOWN-REGULATE A GENE OF INTEREST FOR MNV
INFECTION
Lentiviral vectors produced in Support Protocol 6 can be also used to transduce
macrophage cell lines (e.g., RAW 264.7 or BV-2) commonly used for the study of
MNV to stably over-express or down-regulate genes of interest.
Materials
Macrophage cell lines: RAW 264.7 (ATCC cat. no. TIB-71) or BV-2 (Blasi et al.,
1990)
DMEM-10 medium (see recipe)
Lentiviral vectors (Support Protocol 6)
Phosphate-buffered saline (PBS), pH 7.4, sterile (e.g., Life Technologies, cat.
no.10010-023)
Selection drug (optional; e.g., puromycin)
10-cm dishes, tissue-culture treated
Sterile cell lifter (e.g., Fisher Scientific, cat. no. 08 100 240)
Additional reagents and equipment for counting cells (Phelan, 006)
1. Seed 4 × 106 RAW 264.7 cells or 2 × 106 BV-2 cells in 10 ml DMEM-10 in a tissue
culture-treated 10-cm dish approximately 24 hr before transduction.
The expected cell density at the time of transduction is 30% to 40% confluency.
2. On the day of transduction, add half of the lentiviruses (10 ml) produced in Support
Protocol 6 onto the 10-cm dish of macrophage cell lines. Incubate for 3 days in 37°C,
5% CO2 incubator.
In general, for efficient transduction without titration of the produced lentivirus, match the
size of plate of cells for transduction to the size of plate for the preparation of lentivirus.
If necessary, scale down the size of plates for both lentivirus production and transduction
proportionally. Biosafety Level 2 (BSL-2) practices are required for handling of lentivirus.
3. Three days later, discard the culture medium containing lentivirus, wash once with
10 ml PBS, and add 5 ml of cold DMEM-10. Scrape off the cells with cell lifter,
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down, and transfer them to a 50-ml conical centrifuge tube. Count the number of cells
(Phelan, 2006).
The transduced cells can be analyzed directly at this time or they can be replated for further
selection by the expression of a reporter gene (e.g., green fluorescent protein from pCDH-
MCS-T2A-copGFP-MSCV) or drug-resistance gene (e.g., puromycin N-acetyltransferase
from pLKO.1 puro).
4. Optional: For the drug selection of transduced cells, replate cells at 1 × 106 RAW
264.7 cells or 0.5 × 106 of BV-2 cells per well in 2 ml of DMEM-10 for 6-well
tissue culture plates. At 24 hr after seeding, add drug (e.g., 5 μg/ml puromycin) for
3 days.
The selective concentration of drug for individual cell lines should be titrated before the
selection in a pilot experiment. The duration and frequency of drug treatment should be




TRANSFECTION OF INFECTIOUS VIRAL RNA INTO MOUSE
EMBRYONIC FIBROBLASTS
Macrophages and dendritic cells are the only reported cell types that can be infected
by MNV (Wobus et al., 2004). However, as shown in the example of reverse genetics
systems for MNV, MNV can replicate in many other cell types as long as its infectious
genome is delivered into host cells (Yunus et al., 2010). For example, mouse embryonic
fibroblasts (MEFs) are one cell type that cannot be infected by MNV but can support
MNV replication (Hwang et al., 2012). MEFs isolated from genetically manipulated
mouse lines are a valuable tool to study the function of mutated genes for viral replication
under well-defined culture condition. In this protocol, viral RNA of MNV purified from
concentrated viral stock (Support Protocol 7) is transfected into MEFs (Support Protocol
8) by Lipofectamine 2000 to produce infectious MNV. The procedure optimally yields
5 × 106 plaque-forming units of MNV per 1 μg of transfected viral RNA.
Materials
MEFs (Support Protocol 8)
DMEM-10 medium (see recipe)
Opti-MEM I medium (Invitrogen)
Viral RNA of MNV (Support Protocol 7)
Lipofectamine 2000 (Life Technologies)
24-well tissue culture–treated plates
1. Seed 1 × 104 MEF cells in 1 ml DMEM-10 per well in tissue culture-treated 24-well
plates 24 hr before transfection.
The expected cell density at the time of transfection is 30% to 40% confluency. 0.5 ml
medium per well will be sufficient for 24-well plates, but 1 ml medium is recommended for
even distribution of cells on the plate. Clumped cells significantly lower the transfection
efficiency and viral yield. If necessary, drugs (e.g., interferon γ ) can be used to treat cells
at 12 hr prior to transfection.
2. On the day of transfection, prepare transfection mix as follows according to the
manufacturer’s instruction:
a. Dilute 0.2 to 0.5 μg of infectious viral RNA in 50 μl of Opti-MEM I medium.
Mix gently.
Handling of RNA requires extra caution to minimize any possible contamination
with RNase and subsequent degradation of RNAs. Animal RNA
Viruses
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b. Mix Lipofectamine 2000 gently by inverting the tube three times and dilute
2 μl in 50 μl of Opti-MEM I medium. Mix gently by swirling and incubate for
5 min at room temperature.
c. After the 5-min incubation, combine the diluted RNA with the diluted Lipo-
fectamine 2000. Mix gently by swirling and incubate for 20 min at room
temperature.
3. Add the 100 μl of RNA–Lipofectamine 2000 complexes to each well of cells and
mix gently by rocking the plate perpendicularly a couple of times.
4. Incubate cells at 37°C in a 5% CO2 incubator for 24 hr.
5. To harvest MNV, freeze/thaw the entire 24-well plate by placing it at −80°C and later
at room temperature.
Virus-containing lysate can then be easily transferred into tubes and stored at −80°C for
follow-up assays.
Approximately 1 × 106 plaque forming units of MNV are produced per transfection
(Hwang et al., 2012). Other liposome-mediated transfection reagents may be used, but
Lipofectamine 2000 worked most reproducibly and produced the highest titer of viruses.
SUPPORT
PROTOCOL 7
PREPARATION OF INFECTIOUS VIRAL RNA FROM MNV STOCK
Infectious viral RNA of MNV can be extracted directly from concentrated viral stocks
(Support Protocol 1) using the standard TRIzol method. The genome-linked VPg protein,
which is essential for the translation of viral RNA, stays functional after RNA preparation
with TRIzol unless the RNA is treated with proteases.
Materials
Concentrated MNV virus stock (Support Protocol 1)




RNase-free H2O (APPENDIX 2A, or purchase, e.g., from Invitrogen)
Water bath or heat block (55° to 60°C)
1. Prepare concentrated MNV virus stock (Support Protocol 1) and add appropriate
volume of TRIzol to homogenize, according to the manufacturer’s instruction.
Concentrated viral stock is recommended as starting material for better estimation of
viral yield upon transfection of infectious viral RNA. However, a regular MNV stock can
also be used as starting material.
Depending on the type of TRIzol used (e.g., TRIzol versus TRIzol LS), adjust the volume
of added TRIzol. This protocol is based on the use of regular TRIzol, and thus 10 volumes
(i.e., 1 ml for 0.1 ml viral stock) of TRIzol are used.
2. Incubate the homogenate at room temperature for 5 min, then add 0.2 ml chloroform
per 1 ml of TRIzol used.
3. Shake the samples vigorously for 15 sec, then incubate the resulting mixture at room
temperature for 2 to 3 min.
4. Centrifuge the samples 15 min at 12,000 × g, 4°C.
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5. Transfer the aqueous phase (transparent solution on top of pink solution) to a new
microcentrifuge tube.
The volume of the aqueous phase will be 60% of the volume of TRIzol used.
6. Add 0.5 ml of isopropanol per 1 ml of TRIzol used initially, and incubate at room
temperature for 10 min to precipitate RNA.
7. Centrifuge 10 min at 12,000 × g, 4°C, and remove the supernatant.
The pellet of viral RNA may or may not be visible on the centrifugal side of the tube,
depending on the amount of starting material used. Try not to touch the centrifugal side
while removing the supernatant.
8. Add 1 ml of 75% ethanol, per 1 ml of TRIzol used, to the centripetal side of the
tube. Mix the sample by inverting the tube a couple of times and centrifuge 5 min
at 7500 × g, 4°C.
9. Remove supernatant, spin the tubes briefly again, and remove as much remaining
supernatant as possible.
Another brief centrifugation is recommended to bring down any residual ethanol on the
side of tube and thus to remove the ethanol wash more effectively.
10. Air-dry the RNA at room temperature for 5 min, add the appropriate volume of
RNase-free water to the centrifugal side of the tube, and incubate the samples at
60°C for 15 min. Keep the tubes with dissolved RNA on ice while measuring the
concentration of RNA, and then keep the RNA at −80°C until used.
SUPPORT
PROTOCOL 8
PREPARATION OF MOUSE EMBRYONIC FIBROBLAST CELLS
MEFs are usually isolated from mouse embryos at embryonic day 13.5 (E13.5) to E15.5,
but it can be prepared as early as E8.5 if the embryos have lethal mutations. It is
recommended to prepare both control MEFs and mutant MEFs from mice with same
backgrounds to minimize phenotypic variation due to different genetic background.
NOTE: All protocols involving live animals must be reviewed and approved by an
Institutional Animal Care and Use Committee (IACUC) and must conform to government
regulations for the care and use of laboratory animals.
Materials
Pregnant female mouse
Phosphate-buffered saline (PBS), pH 7.4, sterile (e.g., Life Technologies, cat.
no.10010-023)
70% ethanol
DMEM-10 medium (see recipe)





175-cm2 tissue culture flasks
50-ml conical tubes (e.g., BD Falcon)
Additional reagents and equipment for mouse euthanasia (APPENDIX 3N) and
immortalization of fibroblasts (Xu, 2005)
1. Prepare two 10-cm petri dishes with 20 ml of PBS. Animal RNA
Viruses
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2. Euthanize a pregnant female mouse with embryos of desired genetic background
according to the guidelines of the home institution (e.g., CO2 asphyxiation, then
cervical dislocation; see APPENDIX 3N). Briefly sterilize the euthanized mouse either
by spraying sufficient 70% ethanol to cover the whole body or by soaking the mouse
in 70% ethanol.
Dissection in a clean environment (e.g., inside biosafety cabinet) is recommended to
minimize any contamination.
3. Cut through and peel off abdominal skin and open peritoneum. Dissect out the
entire uterus containing all embryos without damaging the other internal organs and
transfer the uterus to a 10-cm petri dish with PBS.
Damaging the other internal organs, especially intestines, can lead to bacterial contam-
ination.
4. Remove the mouse carcass, clean up the biosafety cabinet, and get a new pair of
gloves and sterile equipment if necessary.
If the dissection equipment is going to be used again, make sure to clean and sterilize
with 70% ethanol.
5. Cut out the uterine wall and take out individual embryos. Transfer all embryos into
the other 10-cm dish with 20 ml PBS.
Remove maternal materials as much as possible, especially when the genetic background
of embryos differs from that of their mother (e.g., embryo with homozygous genetic
knock-out from heterozygous mother).
6. Count the number of embryos, and prepare new 10-cm dishes with 10 ml PBS each
(prepare twice as many dishes as the number of embryos).
7. Transfer each embryo individually into a 10-cm dish. Remove and discard internal
organs, limbs, and head of embryo. Transfer the torso of each embryo to a new
10-cm dish with PBS.
Keep a small piece of a discarded part of the embryo for DNA extraction and subsequent
genotyping if necessary.
8. Using the plunger from a 10-ml syringe, crush the torso as much as possible.
Resuspend the crushed pieces with PBS and transfer them to a 15-ml tube. Centrifuge
5 min at 300 × g, room temperature.
9. Discard supernatant and resuspend the pellet with 10 ml DMEM-10. Transfer the
resuspended pieces of the crushed embryo into a 175-cm2 flask and add 20 ml more
DMEM-10.
10. Incubate the flask in 37°C, 5% CO2 incubator for 7 days.
MEFs grow out from the tissue debris of the crushed embryo. Shake the flask once a
day to spread out the tissue debris for maximal use of the space and even distribution of
MEFs in the flask.
11. Discard medium and loosely bound debris. Add 30 ml PBS to the flask and swirl
it to detach any loosely bound debris. Discard PBS and any debris and add 5 ml of
trypsin/EDTA. Incubate the flask at 37°C for 5 min.
12. Resuspend the cells with 25 ml more DMEM-10 medium and transfer to 50-ml
conical tube.
At this stage, if necessary, any remaining clumps or debris can be removed by allowing
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13. Centrifuge 5 min at 300 × g, room temperature. Discard supernatant and resuspend
the pellet with 30 ml DMEM-10. Split the resuspended cells into three 175-cm2
flasks and add 20 ml more DMEM-10 to each flask. Incubate the flask in 37°C, 5%
CO2 incubator for 2 days.
These are the passage 1 (P1) MEFs.
14. Upon confluency (usually, in 2 days), subculture the P1 MEFs for experiments or
freeze them down (5 × 106 cells/vial in DMEM-10 with 10% v/v DMSO). Use the
primary MEFs until P5 (based on 1:3 split).
The typical yield of P1 MEFs is 2–3 × 107 cells per embryo.
15. To make a stable line of MEF, immortalize the MEFs (Xu, 2005) either by seriaxl
passage (20 to 25 times) or transformation with oncogene (e.g., SV40 large T
antigen).
REAGENTS AND SOLUTIONS
Use deionized, distilled water for all recipes and protocol steps unless otherwise specified. For
common stock solutions, see APPENDIX 2A; for suppliers, see SUPPLIERS APPENDIX.
CMG14-12 conditioned medium
CMG14-12 (Takeshita et al., 2000) is a mouse Ltk– cell line expressing large amounts
of murine M-CSF. CMG14-12 cells [can be obtained from Dr. Seungmin Hwang,
Dept. of Pathology, University of Chicago, with written permission from Dr. A. Kudo
(akudo@bio.titech.ac.jp)] are cultured in α-MEM until confluent. CMG14-12 con-
ditioned medium is then harvested every other day, five times. Culture supernatants
are filtered through a 0.22-μm nitrocellulose filter, divided into 50-ml aliquots, and
stored at −80°C until use.
DMEM-10 medium, complete
High glucose DMEM supplemented with:




1 mM nonessential amino acids
2 mM L-glutamine
Store up to 4 weeks at 4°C
ELISA blocking buffer
Supplement ELISA coating buffer (see recipe) with 3% (w/v) BSA. Prepare fresh.
ELISA coating buffer
1.53 g disodium trioxocarbonate (IV) (sodium carbonate; Na2CO3)
2.93 g sodium hydrogen trioxocarbonate (IV) (sodium bicarbonate; NaHCO3)
Check pH (should be pH 8.8 to 9.6), then bring to 1 liter with H2O
Store up to 3 months at room temperature
ELISA substrate buffer
To make 2 liters:
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25.6 g disodium hydrogen tetraoxophosphate (V) (Na2HPO4)
Adjust pH to 4.2, bring to 2 liters with Milli-Q H2O
Add 1.096 g 2,2′-azino-bis(3-ethylbenzothiazoline-6-sulfonic acid) (ABTS)
Aliquot 12 ml/tube and store at −20°C
Add 12 μl 30% hydrogen peroxide (H2O2) right before adding to ELISA plate
Buffer composition: 0.1 M sodium citrate/1 mM ABTS/0.016% (v/v) H2O2.
ELISA III buffer
0.15 M sodium chloride (NaCl)
0.001 M ethylenediaminetetraacetic acid (EDTA)
0.05 M Tris hydrochloride
0.05% (v/v) Tween 20
Adjust pH to 7.4
Bring to 1 liter with H2O
Add BSA to 0.1% (w/v)




Store up to 3 months at room temperature
HEPES-buffered saline (HeBS), 2×
Dissolve the following reagents in 800 ml of molecular biology–grade water:
16.36 g NaCl (mol. wt. 58.44, 0.28 M final)
11.9 g HEPES (mol. wt. 238.3, 0.05 M final)
0.213 g anhydrous Na2HPO4 (mol. wt. 142, 1.5 mM final)
Adjust pH to 7.05 with 5 M NaOH
Add more molecular biology–grade H2O to 1000 ml final
Filter sterilize through a 0.22-μm nitrocellulose filter
Divide into 50-ml aliquots
Store at 4°C for short-term use or at −20°C for long-term storage
An exact pH is extremely important for efficient transfection. The optimal pH range is 7.05 to
7.12. There can be wide variability in the efficiency of transfection obtained between different
batches of 2× HeBS. Efficiency should be checked with each new batch.
Macrophage complete medium
Add the following reagents to 700 ml of Dulbecco’s modified Eagle medium
(DMEM):
100 ml fetal bovine serum (FBS)
50 ml horse serum
10 ml 200 mM L-glutamine
10 ml of 100 mM sodium pyruvate
100 ml of CMG14-12 conditioned medium [see recipe; equivalent to mouse
M-CSF or L-929 conditioned medium (Stanley et al., 1983)]
Adjust volume to 1000 ml with DMEM
Store up to 2 months at 4°C
MEM medium, 2×, complete
2× MEM (Life Technologies, cat. no. 11935) supplemented with:














Equilibrate to 37°C before use
Store at 4°C for up to 1 month
Seaplaque agarose, 3%
Add 3 g of SeaPlaque agarose (Lonza, cat no. 50100) in a total volume of 100 ml of
distilled water (3% w/v) in a glass bottle. Autoclave 20 to 30 min (it is important to
equilibrate SeaPlaque agarose to 42°C in a water bath before use). Store autoclaved
Seaplaque up to 1 month at room temperature and reheat in microwave prior to use.
COMMENTARY
Background Information
MNV reverse genetics: Reverse genetics
serves as a cornerstone for unraveling the life
cycle of many viruses, allowing the recov-
ery of genetically defined wild-type or mutant
strains, making it a very important tool in mod-
ern virology. As other reverse genetics sys-
tems were established for other members of the
Caliciviridae family, efforts have been made
to introduce a system with MNV, resulting in
a total of three reverse genetics systems to
date (Chaudhry et al., 2007; Ward et al., 2007;
Yunus et al., 2010). The two DNA-based re-
verse genetics systems rely on either the DNA
polymerase II promoter or the T7 polymerase
promoter to drive expression of viral cDNA af-
ter transfection of a DNA plasmid containing
the full-length MNV genome into easily trans-
fectable cells, typically HEK293T cells. The
method by Ward et al. (2007) (see Basic Proto-
col 3) relies on the use of a DNA polymerase
II promoter to generate a capped transcript.
Another method which has proven successful
for the recovery of FCV is the transcription
of RNA from transfected cDNA, driven by
the T7-RNA polymerase from vaccinia virus
(MVA-T7; Geissler et al., 1999). However,
this method failed when applied to the recov-
ery of MNV, as MVA-T7 replication interferes
with the translation and replication of MNV
(Chaudhry et al., 2007). Therefore, Alternate
Protocol 2, based on FPV-T7, constitutes an
improved modification of initial attempts car-
ried out with MVA-T7. Although both FPV
and MVA are members of the Poxviridae fam-
ily, FPV displays a tropism only for avian
cells, and its replication in mammalian cells
is defective. This allows the production of the
T7 RNA polymerase, which drives the syn-
thesis of the transfected MNV cDNA via the
T7 promoter without interfering with MNV
translation and replication as observed with
MVA-T7. Generating infectious MNV from
cDNA cannot be undertaken using cell lines
in which MNV is known to replicate, such
as RAW 264.7 cells, due to difficulties trans-
fecting these cells. Instead, commonly used
transfectable cell lines can be used to recover
the virus, mainly HEK293T cells, but HepG2,
BHK-21, or COS-7 cells have also been tested
(Chaudhry et al., 2007; Ward et al., 2007).
BSR-T7 is a cell line derived from BHK-21
stably expressing T7 RNA polymerase. How-
ever, the expression of T7 RNA polymerase
in these cells is insufficient to recover MNV
from cDNA. This might be due to the low T7
RNA polymerase expression levels detected
in these cells compared to FPV-T7 infected
cells, along with the absence of capping en-
zymes provided by FPV-T7 that could be pro-
viding a cap to the produced MNV transcripts.
Since the transfectable cell lines are not sus-
ceptible to MNV infection, however, reported
titers represent a single replication cycle and
can provide information on the fitness of the
recovered virus.
The RNA-based reverse genetic system
(Basic Protocol 4) described herein represents
the most efficient recovery of genetically de-
fined MNV in cell culture compared to DNA-
based reverse genetics systems. The transfec-
tion of capped RNA, which can be recognized
by the cellular translation machinery, effec-
tively bypasses the absolute requirement for
the covalent linkage of VPg to the 5′ end of
the viral RNA genome (Yunus et al., 2010).
When transfected into BV-2 cells, virus titers
recovered with RNA-based reverse genetics
systems are similar to those obtained by trans-
fection of viral VPg-linked RNA purified from
infected cell cultures (Chaudhry et al., 2007;
Yunus et al., 2010). A more direct and of-
ten more cost effective method for the re-
covery of infectious MNV from capped RNA
transcripts is via transfection into permissive Animal RNAViruses
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BSR-T7 cells. Given that BV-2 cells or RAW
264.7 cells are difficult to transfect using lipid-
based approaches, other cell lines can be used,
such as BSR-T7 cells, a derivative of the BHK-
21 cell line. These cells are easy to trans-
fect and are permissive to MNV replication,
but do not allow multiple rounds of infec-
tion. There are other cell lines also suitable
to this approach, including human 293T cells,
human hepatocellular carcinoma Huh7 cells,
and African green monkey Cos7 cells.
MNV qRT-PCR: A quantitative poly-
merase chain reaction (qPCR) is a modifica-
tion of the polymerase chain reaction (PCR),
where amplification and simultaneous quan-
tification of one or more targeted DNA se-
quences is achieved (Higuchi et al., 1992). Ad-
ditionally, quantitation and amplification can
be visualized in real time because the assay
is fluorescence-based, which, with the proper
controls, can allow for detection of absolute
levels of template (Higuchi et al., 1992; Bustin
et al., 2009). The technique originally arose in
the 1990s (Higuchi et al., 1992) when it was
observed that ethidium bromide had the ca-
pacity to fluoresce and that this fluorescence
increased in the presence of double-stranded
DNA. This fluorescence could be monitored
externally and could allow for determination
of nucleic acid quantity. Thus, the ability
to simultaneously amplify specific DNA se-
quences and detect the product of the amplifi-
cation allowed this technique to revolutionize
modern molecular biology.
Quantitative polymerase chain reaction has
the capacity to detect nucleic acids in a wide
range of samples from numerous sources:
mammalian eukaryotic single cells and tissues,
plant cells and tissues, prokaryotes, stool sam-
ples, and complex fluids (e.g., blood, plasma,
saliva). The quantity of amplified DNA can
then be calculated as either an absolute number
of copies or a relative amount when normal-
ized to input DNA input or additional normal-
izing genes/parameters. Additionally, the tech-
nique has been modified to make it safer for
handling by utilizing alternate fluorophores,
such as fluorescein, that are minimally if at
all toxic. This has made the technique easier
and more accessible, to the point of allowing
several modifications of it to flourish.
Different kinds of qPCR have been devel-
oped in the past years. For example, multiplex
qPCR allows for the simultaneous detection
of more than one nucleic acid sequence in a
single tube through the use of specific fluo-
rescent probes targeting each sequence indi-
vidually. If no specific probes are available,
the use of the double-stranded DNA-binding
dye SYBR Green can allow for amplicon de-
tection. qPCR has also been modified to in-
clude a coupled reverse transcription step (RT-
qPCR) where RNA is used as the starting
template, converted to cDNA, and then subse-
quently amplified. The technology is usually
able to estimate mRNA abundance/gene ex-
pression with a remarkable degree of certainty
and sensitivity. Indeed, this sensitivity of the
technique, for example, can be assessed when
comparing it to older methods of measuring
nucleic acid abundance (e.g., northern blotting
for mRNA). In contrast to older techniques, it
requires minimal amounts of template and is




Propagation and purification of MNV
i. Healthy cells are a prerequisite for opti-
mal virus growth. Cells should be split at least
twice after thawing before using them for virus
infections. RAW 264.7 cells do not grow to
100% confluency. Instead cells will grow on
top of each other and clump. Thus, cells should
be split at 90% confluency before they pile
up.
ii. Not all MNV strains cause the clear CPE
seen with MNV-1. For those strains, it may
be necessary to determine the optimal time
of harvest by performing a viral growth curve
(i.e., infect cells with MNV as described in
Basic Protocol 1 and take samples every 6 to
12 hr to determine viral titers).
iii. If the yield of purified virus is low,
check the starting titer of your virus stock.
Thus, is it advisable while optimizing the pro-
tocol to save a few microliters of virus at each
step of the protocol to check for increase in
purity and/or virus titer.
MNV ELISA
i. The development time should not exceed
10 min, as eventually all samples will turn
color.
ii. Plates should not dry out. If multiple
ELISA plates are processed at one time, let
plates sit in wash buffer, then flick out the
buffer one plate at a time and add new solution
to the plate before proceeding to the next plate.
DNA-based, pol II-driven generation of
recombinant MNV
i. Increasing DNA concentration might im-
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ii. Incubation times are crucial. You need
to find a good balance in having long trans-
fection times and keeping the cells happy. If
you change the medium after 24 hr, keep the
supernatant and test it for virus.
iii. Make sure you do not have plasmid con-
tamination in your analysis should you use
RT-PCR on recombinant virus that does not
plaque.
iv. Make sure you have healthy 293T cells;
maybe test EGFP transfection efficiency first
(especially when using new serum). My-
coplasma contamination negatively affects
transfection efficiency, and you do not want
them in your virus preps anyway.
v. You may want to keep 293T and RAW
264.7 cell medium separate. 293T easily get
contaminated with mycoplasma.
vi. Make sure you have true 293T—if
293Ts change their behavior over time, e.g.,
they do not come off surfaces easily anymore,
this could be HeLa cell contamination (the two
cell lines look pretty much identical).
vii. 293T are bad cells for immunofluores-
cence, since they come off easily and change
shape during treatment.
DNA-based, T7-driven generation of
recombinant MNV
i. Seeding density: This protocol is opti-
mized for the use of BHK or its derivative
cell line, BSR-T7. The seeding densities de-
scribed for these two cell lines are designed to
provide a confluent cell monolayer for trans-
fection with Lipofectamine 2000. The cor-
rect seeding density should be determined for
any other cell line that is to be used. All
these transfectable cell lines are permissive
to MNV replication, but they are not sus-
ceptible to infection as they cannot be in-
fected by MNV; thus, the virus yields ob-
tained represent that from a single round of
replication.
ii. cDNA transfection: The quality of the
cDNA prepared can affect the recoveries. DNA
preparations must be clear of any contami-
nating endotoxin for optimal transfection effi-
ciency.
iii. FPV-T7 titration: The FPV-T7 should
be titrated before use and used to inocu-
late cells at a multiplicity of infection of 0.5
pfu/cell, based on the titer in primary CEFs.
Otherwise, a higher multiplicity of infection
can affect cell viability while a lower multi-
plicity of infection can result in insufficient
cells infected and insufficient T7 polymerase
expression. Both scenarios can affect virus
yields.
iv. The titration of an FPV-T7 stock gen-
erated as mentioned above is performed by
plaque assay in CEFs under solid overlay con-
taining 1% agarose, as previously described
(Buttigieg et al., 2013). Typically, a functional
titration of the newly generated virus stock is
performed. To this end, we compare MNV re-
covery yields of a well-characterized stock of
FPV-T7 with the new preparation to ensure
batch-to-batch comparability. Additional op-
tions for titration other than plaque assay in
primary CEFs include the use of an immuno-
focal assay for T7 RNA polymerase or the use
of a reporter assay reliant on luciferase expres-
sion under the control of a T7 RNA polymerase
promoter.
v. Low titers of infectious MNV can be due
to a variety of reasons. Either poor transfection
efficiency or a cDNA clone that carries delete-
rious mutations can culminate in low recovery
yields. To determine the cause of low titers,
a duplicate for each recovery should be per-
formed. One sample would to be used to titer
the recovered virus, while the other would be
tested for protein extraction. NS7 detection by
western blot permits the analysis of protein
expression levels; a weak signal may signify
a low transfection efficiency, resulting in low
virus titers. If this is the case, first check the
integrity of the cDNA clone using restriction
digestion and sequencing. Then, ensure that
the purity of the DNA is sufficient, and finally
use different ratios of cDNA:Lipofectamine
and/or extended incubation periods to improve
the efficiency of virus recovery. Conversely,
detecting a strong signal for NS7 is a sign
of good transfection efficiency. Hence, lower
virus yields than in wild-type preparations typ-
ically suggests that the viral cDNA encodes for
a lower fitness virus.
RNA-based generation of recombinant
MNV
i. The quality of linearized MNV cDNA
and subsequently synthesized genomic RNA
are the key parameters for effective recovery
of infectious MNV.
ii. Ensure an RNase-free environment is
maintained throughout the protocol. Degrada-
tion of RNA will compromise the final yield
and may lead to failure to recover infectious
viral particles.
iii. Adhere to the step annotations in the
protocol for key advice at each stage.
iv. During the Neon-mediated transfection
of RNA into BV-2 cells, it is important
to prevent the formation of bubbles when
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electroporation will compromise the cell vi-
ability and have negative impact on the final
yield of recovery.
v. If infectious MNV fails to be recovered,
check first whether the capped RNA used for
transfections remained intact. Also, western
blot analysis against the viral proteins (e.g.,
NS7 Pol) may be used to confirm whether the
transfection is successful. The cytopathic ef-
fect (CPE) of MNV on BV-2 cells after >24 hr
post transfection is another indicator of suc-
cessful transfection and production of infec-
tious virus. It is worth noting, however, that
it is possibe that mutant viruses may replicate
without causing CPE. In this situation, viral
RNA should be detected and can be quantified
by qRT-PCR; viral protein expression should
be confirmed by western blot.
TCID50
The most common source of error in
this protocol is accidental contamination and
carry-over of virus from one dilution to an-
other, or the contamination of the medium
or cells used for diluting the virus. To avoid
this, plate out the cells in the test plates
ahead of time, and be sure to exchange tips
at each dilution, and between samples. Per-
forming the TCID50 with a mock sample after
the virus samples should highlight if cross-
contamination has occurred.
Plaque assay
i. Healthy RAW 264.7 cells are critical for
the success of this assay. Do not let cells over-
grow, as those cells do not typically form
plaques. Keep track of the passage number
and use lower passage cells (we use cells be-
low passage 30).
ii. Do not let cell monolayers dry out. Only
process up to five plates at a time.
iii. Carefully count cells when plating, as
no plaques form when cells are too sparse or
too dense.
iv. If no plaques are visible before stain-
ing the monolayer, incubate for an additional
4 hr and check again. The maximum incuba-
tion time should not exceed 72 hr.
v. If no plaques are visible after staining
even at 72 hr, check monolayer with light
microscope. If all cells are dead, likely the
agarose or staining solution was too hot when
adding to the monolayer. If cells are healthy,
they were likely too dense when plated and
unable to form plaques. Alternatively, some
MNV strains do not form plaques, or plaques
are very small and hard to visualize. In that
case use TCID50 protocol (Basic Protocol 5).
MNV qRT-PCR
i. For this protocol, reverse transcription
can be performed as either a single reaction
for cDNA synthesis or coupled to qPCR.
ii. If the sample of interest contains addi-
tional expressed RNA (aside from viral RNA)
that is to be amplified subsequently, it is best
to perform a single reaction for cDNA synthe-
sis using nonspecific primers (e.g., oligo-dT).
This is done in order to avoid the worry of
RNA degradation if several reactions have to
be performed. However, this will only work
for polyadenylated mRNA molecules, and can
skew the reaction toward the most abundant
targets in the sample. If only viral RNA am-
plification is desired, a single-tube one-step
RT-qPCR reaction, where cDNA synthesis is
coupled to amplification by the use of gene-
specific primers, can be performed.
iii. These reactions can be done using
home-made reagents, as long as optimiza-
tion of amplification conditions is performed.
However, the use of commercially available
mixes, when possible, is recommended, as
they contain additives that provide stability to
the reaction components and can also allow
for faster amplification.
Optimization of qPCR amplification should
be performed using the primer/probe matrix
method, temperature gradient optimization for
annealing, and salt concentration modifica-
tions (Lutfalla and Uze 2006; Mikeska and
Dobrovic 2009).
iv. High-quality RNA is crucial for effi-
cient amplification and quantification. Follow
correct isolation and handling technique.
v. Since PCR amplifies all target nucleic
acid, whether from an intact virion, defective
(noninfectious) virions, or free nucleic acids
in solution, qPCR results (expressed in terms
of genome copies/ml) are likely to be higher in
than results obtained through other methods of
viral detection (e.g., TCID50 or plaque assay).
This should be kept in mind when analyzing
the data.
vi. Although the use of DNA standards is
effective in this situation, it is recommended
that, whenever possible, in vitro–transcribed
RNA be used as the standard for the reaction,
since it more accurately reflects the efficiency
of reverse transcription that the unknown sam-
ples will undergo.
vii. The probe should be protected from
light at all times and not stored for long periods
of time in too dilute an aliquot.
viii. If no amplification, poor signal, or no
signal is seen, you have no detectable PCR
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present in the reaction, that you used inade-
quate buffers/master mixes, that you used in-
adequate cycling conditions, that you forgot
the reverse transcription step, or that the probe
and/or the template were degraded.
ix. If a signal is detected in the negative
controls (e.g., no-template control or no RT
control), you may have contamination of your
reaction components, primer dimer formation
due to wrong cycling steps, or contamination
with DNA.
x. In the case of low or high reaction effi-
ciency, there might have been pipetting inac-
curacy in making the standards, primer dimer
formation if conditions are not optimal (wrong
temperature and master mix), or probe quality
is bad.
xi. In case the Cq values of replicate sam-
ples are not similar, the most likely cause is
pipetting inaccuracy.
Strand-specific RT-qPCR
i. It is important to accurately measure
the standard RNA concentration by UV spec-
trophotometry. The OD260 of the RNA should
be between 0.2 to 0.8 to measure the quantity
accurately. If the OD260 is above this range,
dilute the RNA in nuclease free water.
ii. As the protocol deals with repetitive
pipetting of small volume, care should be taken
to minimize the error. Pipets should be care-
fully calibrated, and care should be taken to
ensure that no liquid either adheres to the out-
side of the tips during pipetting or remains
within the tip after mixing of components.
iii. It is important to analyze the melting
curve before extrapolating sample copy num-
ber from the standard curve. The melting tem-
perature of sample wells should be same as
that of standard RNA wells.
iv. It is important to run sufficient negative
controls (no-template control) each time, using
the same aliquot of nuclease-free water that
was used during the protocol.
siRNA transfection of BV-2 cells using
NEON transfection system
i. Cells should not stay in Buffer R for more
than 15 min. It is important to keep the cells
in their appropriate medium until immediately
prior to the first centrifugation in PBS.
ii. A number of protocol changes may be
required if a reduction in target protein expres-
sion is not observed using the standard pro-
tocol. Excessive cell death and failure of the
transfection may also occur as a result of the
formation of bubbles. Extreme care should be
taken to ensure this does not occur. Assuming
efficient transfection has occurred, examples
of changes that may be required include:
a. Design of alternative siRNAs
against the target gene.
b. Use of a combination of pooled
siRNAs targeting the same gene can be ef-
fective.
c. Increasing the concentration of
siRNA used to transfect the cells can in-
crease the efficacy of siRNA.
d. Multiple rounds of transfection
may also be required, but care should be
taken to ensure sufficient cell survival is
maintained.
Preparation of primary bone marrow cells
i. The most common problem in prepar-
ing primary cells is contamination by bacteria
and fungi. Careful sterilization of equipment
and sterile operation techniques are essential
to minimize the risk of contamination.
ii. Culturing the primary cells without an-
tibiotics (e.g., penicillin and streptomycin)
helps to identify and respond to any contami-
nation of cultures quickly.
Production of lentiviral vector
i. Although the 293T cell line is highly
transfectable, transfection efficiency of 293T
cells is the most critical parameter in the pro-
duction of lentiviral vectors.
ii. The right cell density and good health
condition of the 293T cells (including low pas-
sage) and optimal pH of 2× HeBS are critical
factors and need to be well controlled.
Lentiviral transduction of macrophage cell
lines
i. Drug-mediated selection of transduced
cells needs a constant monitoring of drug effect
and titration of optimal drug concentration,
since the screening and subsequent growth of
the transduced cells is significantly affected
by the death of the other cells and consequent
population density.
ii. Too much cell death due to low trans-
duction efficiency can lead to false negative
result (i.e., the death of the transduced cells).
iii. On the contrary, a drug is less effective
in killing untransduced cells if the population
density of treated cells is too high, and this can
lead to false positive result (i.e., the survival
of the untransduced cells).
Time Considerations
Generation of MNV-containing lysate:
Maximum MNV-1 titers following a low-MOI
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to 48 hr. However, the optimal time has to be
individually determined for each MNV strain.
Generation of concentrated MNV stock:
The amount of MNV lysate to be concentrated
determines the length of time required to con-
centrate virus. In one day, 360 ml of lysate
can be concentrated (i.e., two centrifuge runs).
MNV purification: Purification takes 2 to
3 days from start to finish. Day 1 is a long
day and will be spent spinning down large cel-
lular debris, pelleting and resuspending virus,
and preparing the CsCl gradients. Day 2 will
be spent by fractionating the gradient and de-
termining RFI. Alternatively, the procedure
can be performed in 3 days. A good stopping
point is to incubate the virus pellet with PBS
overnight at 4°C. The gradient will then be
prepared on day 2 and fractionated on day 3.
MNV ELISA: The ELISA assay takes 1½
days, with the coating of the plates on day 1,
while the rest is done on day 2. If needed,
coating times can be extended for several days
(e.g., over the weekend).
DNA-based, pol II-driven generation of
recombinant MNV: Transfection of a plas-
mid takes 30 min followed by an incubation
time of at least 48 hr to generate recombi-
nant virus. Amplification of the recombinant
virus on RAW 264.7 cells takes an additional
48 hr. The optional step of plaque purification
will take 2 days. To verify that the mutation
is contained in the virus stock, amplification
of the region of interest by RT-qPCR takes
another day. Sequencing time for the ampli-
con depends on the availability of the local
sequencing core. Alternatively, samples can
be submitted to commercial sequencing facil-
ities, but additional shipping time will need to
be taken into account.
DNA-based, T7-driven generation of re-
combinant MNV: Cell seeding as described in
step 1 typically requires 30 min. Cells can be
left overnight to settle, or for 3 hr if seeded
at double the recommended amount and trans-
fected the same day. Infecting with FPV-T7
and transfecting the cells with desired infec-
tious clones takes a maximum of 3 hr. Cells
can be left to incubate from 24 to 72 hr. After
sufficient incubation time, cells can be frozen
and stored in −80°C until use. After thawing,
cells should be clarified from samples and the
virus-containing supernatant can be aliquotted
and stored at −80°C for further use.
RNA-based generation of recombinant
MNV: Preparation of linearized DNA will take
about 4 hr in total, including 3 hr for restric-
tion digestion and purification. In vitro tran-
scription can be performed within 8 hr de-
pending on how long the reaction is incubated,
the amount of RNA desired, and the method
used to assess the RNA integrity. As mentioned
above, precipitation using LiCl can be per-
formed the same day or the precipitates can
be left overnight. In vitro enzymatic capping
can be performed within 4 hr with subsequent
purification. Depending on the methods, the
recovery of infectious MNV will take half a
day to one day to set up, and up to 3 days will
be required to obtain virus particles, based on
how many hours post-transfection the viruses
are harvested. Obtaining the titer of recovered
viruses will generally take 3 to 4 days, depend-
ing on which titration method is used.
TCID50: With practice, a single TCID50 can
be performed in under 20 min. However, it is
common to process large numbers of samples
in parallel. For example, TCID50 assays of 30
to 40 samples takes 3 to 4 hr. This can be no-
ticeably shortened by the use of an electronic
multichannel pipet (e.g., an Eppendorf Xplorer
Plus) capable of serial dilutions, as this repre-
sents the most time-intensive portion of this
method.
MNV plaque assay: Plating cells takes ap-
proximately 1 hr. On the following day, the
length of the infection is dependent on the
number of samples being analyzed. A typi-
cal assay with 30 to 40 samples takes 3 hr
for virus dilutions, infection, and agarose over-
lay. Plaques are stained 2 to 3 days later, which
takes 30 min for applying the stain, a 2- to 3-hr
incubation for staining, and another hour for
counting plaques and tabulating virus titers.
MNV qRT-PCR: Time for RNA extraction
depends on the number of samples, but if using
a kit it should take from 30 min to a couple of
hours. DNase treatment typically takes about
45 min (more if a large number of samples
are used). qPCR plate setup should take about
15 min, and the run in the thermal cycler takes
about 40 min.
Strand-specific RT-qPCR: The RT step
takes 30 min, and the qPCR program runs
for 2 hr, 40 min. To analyze 10 experimen-
tal samples and standard curve samples, the
complete protocol can be achieved in 4 to 5 hr.
siRNA Transfection of BV-2 cells using
NEON transfection system: Allow 1 hr to
complete this protocol for a single siRNA
transfection and the relevant siRNA transfec-
tion control.
Lentiviral transduction of primary bone
marrow derived macrophages for MNV infec-
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from a mouse should take less than 30 min.
Transfection into a 10-cm dish of 293T cells
takes about 40 min and each harvesting should
take less than 1 min per dish. Filtration of the
final lentiviral vector preparation takes about
5 min per virus. If bone marrow progenitor
cells and transfectable 293T cells are prepared
on Day 0, the 293T cells is transfected on
Day 1 and the resulting lentiviral stocks are
harvested Day 2 and 3. Bone marrow-derived
macrophages are transduced on Day 4 and 5
and are ready for replating on Day 7 (Day 9 in
case of drug selection). The transduced cells
become ready for MNV infection at 3 days
after replating.
Transfection of infectious viral RNA into
MEFs: Isolating embryos from a pregnant fe-
male mouse and setting up culture for MEF
takes less than 2 hr. An additional 9 days are
required to generate passage-1 MEFs from the
day of embryo isolation. Extraction of infec-
tious viral RNA from the concentrated stocks
of MNV takes about 1 hr. The transfection of
the viral RNA into MEFs takes about 40 min,
and generation of infectious MNV from the
transfected MEFs takes a day.
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A protocol for the generation of a neutral red-
containing MNV stock to measure replicating virus




A video for the generation of recombinant MNV can
be found at this site.
http://www.lindenbachlab.org/resources.html
Excel spreadsheet for calculating TCID50 values.
http://www.jove.com/video/4297/plaque-
assay-for-murine-norovirus
A video for the plaque assay can be found at this
site.
http://www.endmemo.com/bio/dnacopynum.php
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